<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39459002</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1424-8247</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>12</Day></PubDate></JournalIssue><Title>Pharmaceuticals (Basel, Switzerland)</Title><ISOAbbreviation>Pharmaceuticals (Basel)</ISOAbbreviation></Journal><ArticleTitle>Multifaceted Heparin: Diverse Applications beyond Anticoagulant Therapy.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1362</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ph17101362</ELocationID><Abstract><AbstractText>Heparin, a naturally occurring polysaccharide, has fascinated researchers and clinicians for nearly a century due to its versatile biological properties and has been used for various therapeutic purposes. Discovered in the early 20th century, heparin has been a key therapeutic anticoagulant ever since, and its use is now implemented as a life-saving pharmacological intervention in the management of thrombotic disorders and beyond. In addition to its known anticoagulant properties, heparin has been found to exhibit anti-inflammatory, antiviral, and anti-tumorigenic activities, which may lead to its widespread use in the future as an essential drug against infectious diseases such as COVID-19 and in various medical treatments. Furthermore, recent advancements in nanotechnology, including nano-drug delivery systems and nanomaterials, have significantly enhanced the intrinsic biofunctionalities of heparin. These breakthroughs have paved the way for innovative applications in medicine and therapy, expanding the potential of heparin research. Therefore, this review aims to provide a creation profile of heparin, space for its utilities in therapeutic complications, and future characteristics such as bioengineering and nanotechnology. It also discusses the challenges and opportunities in realizing the full potential of heparin to improve patient outcomes and elevate therapeutic interventions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sultana</LastName><ForeName>Razia</ForeName><Initials>R</Initials><Identifier Source="ORCID">0009-0003-2453-5165</Identifier><AffiliationInfo><Affiliation>Department of Chemical Engineering, Faculty of Engineering, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819-0395, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biotechnology and Genetic Engineering, Faculty of Science, Noakhali Science and Technology University, Noakhali 3814, Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamihira</LastName><ForeName>Masamichi</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2570-5712</Identifier><AffiliationInfo><Affiliation>Department of Chemical Engineering, Faculty of Engineering, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819-0395, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>JPMJTR22U9</GrantID><Agency>Japan Science and Technology Agency</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pharmaceuticals (Basel)</MedlineTA><NlmUniqueID>101238453</NlmUniqueID><ISSNLinking>1424-8247</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">anticoagulant</Keyword><Keyword MajorTopicYN="N">bioengineering</Keyword><Keyword MajorTopicYN="N">glycosaminoglycan</Keyword><Keyword MajorTopicYN="N">heparin</Keyword><Keyword MajorTopicYN="N">nano-drug delivery systems</Keyword><Keyword MajorTopicYN="N">nanotechnology</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39459002</ArticleId><ArticleId IdType="pmc">PMC11510354</ArticleId><ArticleId IdType="doi">10.3390/ph17101362</ArticleId><ArticleId IdType="pii">ph17101362</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chen D. Heparin beyond anti-coagulation. Curr. Res. Transl. Med. 2021;69:103300. doi: 10.1016/j.retram.2021.103300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.retram.2021.103300</ArticleId><ArticleId IdType="pmc">PMC8257468</ArticleId><ArticleId IdType="pubmed">34237474</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu M., Huang S., Luo C., Wu Z., Liang B., Huang H., Ci Z., Zhang D., Han L., Lin J. Pharmacological and clinical application of heparin progress: An essential drug for modern medicine. Biomed. Pharmacother. 2021;139:111561. doi: 10.1016/j.biopha.2021.111561.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2021.111561</ArticleId><ArticleId IdType="pubmed">33848775</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao C., Xu H., Yu L., Zhang L. Heparin: An essential drug for modern medicine. Prog. Mol. Biol. Transl. Sci. 2019;163:1–19. doi: 10.1016/bs.pmbts.2019.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.pmbts.2019.02.002</ArticleId><ArticleId IdType="pubmed">31030744</ArticleId></ArticleIdList></Reference><Reference><Citation>Zang L., Zhu H., Wang K., Liu Y., Yu F., Zhao W. Not Just Anticoagulation—New and Old Applications of Heparin. Molecules. 2022;27:6968. doi: 10.3390/molecules27206968.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules27206968</ArticleId><ArticleId IdType="pmc">PMC9609994</ArticleId><ArticleId IdType="pubmed">36296562</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P., Chi L., Zhang Z., Zhao H., Zhang F., Linhardt R.J. Heparin: An old drug for new clinical applications. Carbohydr. Polym. 2022;295:119818. doi: 10.1016/j.carbpol.2022.119818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.carbpol.2022.119818</ArticleId><ArticleId IdType="pubmed">35989029</ArticleId></ArticleIdList></Reference><Reference><Citation>McLean J. The thromboplastic action of cephalin. Am. J. Physiol.-Leg. Content. 1916;41:250–257. doi: 10.1152/ajplegacy.1916.41.2.250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplegacy.1916.41.2.250</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemker H.C. A century of heparin: Past, present and future. J. Thromb. Haemost. 2016;14:2329–2338. doi: 10.1111/jth.13555.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.13555</ArticleId><ArticleId IdType="pubmed">27862941</ArticleId></ArticleIdList></Reference><Reference><Citation>Best C.H. Preparation of heparin and its use in the first clinical cases. Circulation. 1959;19:79–86. doi: 10.1161/01.CIR.19.1.79.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.19.1.79</ArticleId><ArticleId IdType="pubmed">13619024</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinkhous K.M., Smith H.P., Warner E.D., Seegers W.H. The inhibition of lood clotting: An unidentified substance which acts in conjunction with heparin to prevent the conversion of prothrombin into thrombin. Am. J. Physiol.-Leg. Content. 1939;125:683–687. doi: 10.1152/ajplegacy.1939.125.4.683.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplegacy.1939.125.4.683</ArticleId></ArticleIdList></Reference><Reference><Citation>Waugh D.F., Fitzgerald M.A. Quantitative aspects of antithrombin and heparin in plasma. Am. J. Physiol.-Leg. Content. 1956;184:627–639. doi: 10.1152/ajplegacy.1956.184.3.627.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplegacy.1956.184.3.627</ArticleId><ArticleId IdType="pubmed">13302473</ArticleId></ArticleIdList></Reference><Reference><Citation>Monkhouse F.C., France E.S., SEEGERS W.H. Studies on the antithrombin and heparin co-factor activities of a fraction adsorbed from plasma by aluminum hydroxide. Circ. Res. 1955;3:397–402. doi: 10.1161/01.RES.3.4.397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.RES.3.4.397</ArticleId><ArticleId IdType="pubmed">14390722</ArticleId></ArticleIdList></Reference><Reference><Citation>Abildgaard U. Highly purified antithrombin III with heparin cofactor activity prepared by disc electrophoresis. Scand. J. Clin. Lab. Investig. 1968;21:89–91. doi: 10.3109/00365516809076981.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00365516809076981</ArticleId><ArticleId IdType="pubmed">5637480</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogwood J., Mulloy B., Lever R., Gray E., Page C.P. Pharmacology of Heparin and Related Drugs: An Update. Pharmacol. Rev. 2023;75:328–379. doi: 10.1124/pharmrev.122.000684.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/pharmrev.122.000684</ArticleId><ArticleId IdType="pubmed">36792365</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulloy B., Hogwood J., Gray E., Lever R., Page C.P. Pharmacology of heparin and related drugs. Pharmacol. Rev. 2016;68:76–141. doi: 10.1124/pr.115.011247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/pr.115.011247</ArticleId><ArticleId IdType="pubmed">26672027</ArticleId></ArticleIdList></Reference><Reference><Citation>Thacker B.E., Thorne K.J., Cartwright C., Park J., Glass K., Chea A., Kellman B.P., Lewis N.E., Wang Z., Di Nardo A. Multiplex genome editing of mammalian cells for producing recombinant heparin. Metab. Eng. 2022;70:155–165. doi: 10.1016/j.ymben.2022.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymben.2022.01.002</ArticleId><ArticleId IdType="pubmed">35038554</ArticleId></ArticleIdList></Reference><Reference><Citation>Aláez-Versón C.R., Lantero E., Fernàndez-Busquets X. Heparin: New life for an old drug. Nanomedicine. 2017;12:1727–1744. doi: 10.2217/nnm-2017-0127.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/nnm-2017-0127</ArticleId><ArticleId IdType="pubmed">28635544</ArticleId></ArticleIdList></Reference><Reference><Citation>Folkman J., Langer R., Linhardt R.J., Haudenschild C., Taylor S. Angiogenesis Inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science. 1983;221:719–725. doi: 10.1126/science.6192498.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.6192498</ArticleId><ArticleId IdType="pubmed">6192498</ArticleId></ArticleIdList></Reference><Reference><Citation>Lever R., Page C.P. Novel drug development opportunities for heparin. Nat. Rev. Drug Discov. 2002;1:140–148. doi: 10.1038/nrd724.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd724</ArticleId><ArticleId IdType="pubmed">12120095</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindahl U. ‘Heparin’–from anticoagulant drug into the new biology. Glycoconj. J. 2000;17:597–605. doi: 10.1023/A:1011030711317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1011030711317</ArticleId><ArticleId IdType="pubmed">11421351</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi D., Sheng A., Chi L. Glycosaminoglycan-protein interactions and their roles in human disease. Front. Mol. Biosci. 2021;8:639666. doi: 10.3389/fmolb.2021.639666.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2021.639666</ArticleId><ArticleId IdType="pmc">PMC7985165</ArticleId><ArticleId IdType="pubmed">33768117</ArticleId></ArticleIdList></Reference><Reference><Citation>Torri G., Naggi A. Heparin centenary–an ever-young life-saving drug. Int. J. Cardiol. 2016;212:S1–S4. doi: 10.1016/S0167-5273(16)12001-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0167-5273(16)12001-7</ArticleId><ArticleId IdType="pubmed">27264864</ArticleId></ArticleIdList></Reference><Reference><Citation>Hippensteel J.A., LaRiviere W.B., Colbert J.F., Langouët-Astrié C.J., Schmidt E.P. Heparin as a therapy for COVID-19: Current evidence and future possibilities. Am. J. Physiol. Lung Cell. Mol. Physiol. 2020;319:L211–L217. doi: 10.1152/ajplung.00199.2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.00199.2020</ArticleId><ArticleId IdType="pmc">PMC7381711</ArticleId><ArticleId IdType="pubmed">32519894</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutch C., Thrombosis C. Early Effects of unfractionated heparin on clinical and radiological signs and D-dimer levels in patients with COVID-19 associated pulmonary embolism: An observational cohort study. Thromb. Res. 2021;200:130–132. doi: 10.1016/j.thromres.2021.01.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2021.01.023</ArticleId><ArticleId IdType="pmc">PMC8010503</ArticleId><ArticleId IdType="pubmed">33592531</ArticleId></ArticleIdList></Reference><Reference><Citation>Ennemoser M., Rieger J., Muttenthaler E., Gerlza T., Zatloukal K., Kungl A.J. Enoxaparin and pentosan polysulfate bind to the SARS-CoV-2 spike protein and human ACE2 receptor, inhibiting vero cell infection. Biomedicines. 2021;10:49. doi: 10.3390/biomedicines10010049.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10010049</ArticleId><ArticleId IdType="pmc">PMC8772983</ArticleId><ArticleId IdType="pubmed">35052728</ArticleId></ArticleIdList></Reference><Reference><Citation>Kow C.S., Ramachandram D.S., Hasan S.S. The effect of higher-intensity dosing of anticoagulation on the clinical outcomes in hospitalized patients with COVID-19: A meta-analysis of randomized controlled trials. J. Infect. Chemother. 2022;28:257–265. doi: 10.1016/j.jiac.2021.11.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiac.2021.11.008</ArticleId><ArticleId IdType="pmc">PMC8595354</ArticleId><ArticleId IdType="pubmed">34840039</ArticleId></ArticleIdList></Reference><Reference><Citation>Seffer M.-T., Cottam D., Forni L.G., Kielstein J.T. Heparin 2.0: A new approach to the infection crisis. Blood Purif. 2021;50:28–34. doi: 10.1159/000508647.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000508647</ArticleId><ArticleId IdType="pmc">PMC7445380</ArticleId><ArticleId IdType="pubmed">32615569</ArticleId></ArticleIdList></Reference><Reference><Citation>Thachil J. The versatile heparin in COVID-19. J. Thromb. Haemost. 2020;18:1020–1022. doi: 10.1111/jth.14821.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14821</ArticleId><ArticleId IdType="pmc">PMC9906146</ArticleId><ArticleId IdType="pubmed">32239799</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang L., Zhang T., Lu H., Li S., Lv K., Tuffour A., Zhang L., Ding K., Li J.-P., Li H. Heparin mimetics as potential intervention for COVID-19 and their bio-manufacturing. Synth. Syst. Biotechnol. 2023;8:11–19. doi: 10.1016/j.synbio.2022.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.synbio.2022.10.002</ArticleId><ArticleId IdType="pmc">PMC9595387</ArticleId><ArticleId IdType="pubmed">36313216</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindahl U., Bäckström G., Höök M., Thunberg L., Fransson L.-A., Linker A. Structure of the Antithrombin-Binding Site in Heparin. Proc. Natl. Acad. Sci. USA. 1979;76:3198–3202. doi: 10.1073/pnas.76.7.3198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.76.7.3198</ArticleId><ArticleId IdType="pmc">PMC383791</ArticleId><ArticleId IdType="pubmed">226960</ArticleId></ArticleIdList></Reference><Reference><Citation>Dementiev A., Petitou M., Herbert J.-M., Gettins P.G.W. The Ternary Complex of Antithrombin–Anhydrothrombin–Heparin Reveals the Basis of Inhibitor Specificity. Nat. Struct. Mol. Biol. 2004;11:863–867. doi: 10.1038/nsmb810.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb810</ArticleId><ArticleId IdType="pubmed">15311268</ArticleId></ArticleIdList></Reference><Reference><Citation>Petitou M., van Boeckel C.A.A. A Synthetic Antithrombin III Binding Pentasaccharide Is Now a Drug! What Comes Next? Angew. Chem. Int. Ed. Engl. 2004;43:3118–3133. doi: 10.1002/anie.200300640.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.200300640</ArticleId><ArticleId IdType="pubmed">15199558</ArticleId></ArticleIdList></Reference><Reference><Citation>van Boeckel C.A.A., Petitou M. The Unique Antithrombin III Binding Domain of Heparin: A Lead to New Synthetic Antithrombotics. Angew. Chem. Int. Ed. Engl. 1993;32:1671–1690. doi: 10.1002/anie.199316713.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.199316713</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberg R., Bauer K. The heparin-antithrombin system: A natural anticoagulant mechanism. In: Colman R.W., Hirsh J., Marder V.J., Salzman E.W., editors. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 3rd ed. J.B. Lippincott &amp; Co.; Philadelphia, PA, USA: 1994. pp. 837–860.</Citation></Reference><Reference><Citation>Rosenberg R.D., Lam L. Correlation between structure and function of heparin. Proc. Natl. Acad. Sci. USA. 1979;76:1218–1222. doi: 10.1073/pnas.76.3.1218.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.76.3.1218</ArticleId><ArticleId IdType="pmc">PMC383221</ArticleId><ArticleId IdType="pubmed">286307</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H.N., Whitelock J.M., Lord M.S. Structure-activity relationships of bioengineered heparin/heparan sulfates produced in different bioreactors. Molecules. 2017;22:806. doi: 10.3390/molecules22050806.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules22050806</ArticleId><ArticleId IdType="pmc">PMC6154572</ArticleId><ArticleId IdType="pubmed">28505124</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu L., Suflita M., Linhardt R.J. Bioengineered heparins and heparan sulfates. Adv. Drug Deliv. Rev. 2016;97:237–249. doi: 10.1016/j.addr.2015.11.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2015.11.002</ArticleId><ArticleId IdType="pmc">PMC4753095</ArticleId><ArticleId IdType="pubmed">26555370</ArticleId></ArticleIdList></Reference><Reference><Citation>Capila I., Linhardt R.J. Heparin–protein interactions. Angew. Chem. Int. Ed. Engl. 2002;41:390–412. doi: 10.1002/1521-3773(20020201)41:3&lt;390::AID-ANIE390&gt;3.0.CO;2-B.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1521-3773(20020201)41:3&lt;390::AID-ANIE390&gt;3.0.CO;2-B</ArticleId><ArticleId IdType="pubmed">12491369</ArticleId></ArticleIdList></Reference><Reference><Citation>Casu B., Naggi A., Torri G. Heparin-derived heparan sulfate mimics to modulate heparan sulfate-protein interaction in inflammation and cancer. Matrix Biol. 2010;29:442–452. doi: 10.1016/j.matbio.2010.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.matbio.2010.04.003</ArticleId><ArticleId IdType="pmc">PMC3057403</ArticleId><ArticleId IdType="pubmed">20416374</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulberti S., Mao X., Bui C., Fournel-Gigleux S. The role of heparan sulfate maturation in cancer: A focus on the 3O-sulfation and the enigmatic 3O-sulfotransferases (HS3STs) Semin. Cancer Biol. 2020;62:68–85. doi: 10.1016/j.semcancer.2019.10.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcancer.2019.10.009</ArticleId><ArticleId IdType="pubmed">31711992</ArticleId></ArticleIdList></Reference><Reference><Citation>Baytas S.N., Linhardt R.J. Advances in the preparation and synthesis of heparin and related products. Drug Discov. Today. 2020;25:2095–2109. doi: 10.1016/j.drudis.2020.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2020.09.011</ArticleId><ArticleId IdType="pmc">PMC7718634</ArticleId><ArticleId IdType="pubmed">32947045</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhaskar U., Sterner E., Hickey A.M., Onishi A., Zhang F., Dordick J.S., Linhardt R.J. Engineering of routes to heparin and related polysaccharides. Appl. Microbiol. Biotechnol. 2012;93:1–16. doi: 10.1007/s00253-011-3641-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00253-011-3641-4</ArticleId><ArticleId IdType="pmc">PMC3252477</ArticleId><ArticleId IdType="pubmed">22048616</ArticleId></ArticleIdList></Reference><Reference><Citation>Oduah E.I., Linhardt R.J., Sharfstein S.T. Heparin: Past, Present, and Future. Pharmaceuticals. 2016;9:38. doi: 10.3390/ph9030038.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph9030038</ArticleId><ArticleId IdType="pmc">PMC5039491</ArticleId><ArticleId IdType="pubmed">27384570</ArticleId></ArticleIdList></Reference><Reference><Citation>Suflita M., Fu L., He W., Koffas M., Linhardt R.J. Heparin and related polysaccharides: Synthesis using recombinant enzymes and metabolic engineering. Appl. Microbiol. Biotechnol. 2015;99:7465–7479. doi: 10.1007/s00253-015-6821-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00253-015-6821-9</ArticleId><ArticleId IdType="pmc">PMC4546523</ArticleId><ArticleId IdType="pubmed">26219501</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlsson P., Kjellén L. Heparin—A Century of Progress. Volume 207. Springer; Berlin/Heidelberg, Germany: 2012. Heparin biosynthesis; pp. 23–41. Handbook of Experimental Pharmacology.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-642-23056-1_2</ArticleId><ArticleId IdType="pubmed">22566219</ArticleId></ArticleIdList></Reference><Reference><Citation>Lidholt K., Riesenfeld J., Jacobsson K.G., Feingold D.S., Lindahl U. Biosynthesis of heparin. Modulation of polysaccharide chain length in a cell-free System. Biochem. J. 1988;254:571–578. doi: 10.1042/bj2540571.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/bj2540571</ArticleId><ArticleId IdType="pmc">PMC1135116</ArticleId><ArticleId IdType="pubmed">3178773</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabenstein D.L. Heparin and heparan sulfate: Structure and function. Nat. Prod. Rep. 2002;19:312–331. doi: 10.1039/b100916h.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/b100916h</ArticleId><ArticleId IdType="pubmed">12137280</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaidyanathan D., Williams A., Dordick J.S., Koffas M.A.G., Linhardt R.J. Engineered heparins as new anticoagulant drugs. Bioeng. Transl. Med. 2017;2:17–30. doi: 10.1002/btm2.10042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/btm2.10042</ArticleId><ArticleId IdType="pmc">PMC5412866</ArticleId><ArticleId IdType="pubmed">28516163</ArticleId></ArticleIdList></Reference><Reference><Citation>Glass C.A. Recombinant heparin—New opportunities. Front. Med. 2018;5:341. doi: 10.3389/fmed.2018.00341.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2018.00341</ArticleId><ArticleId IdType="pmc">PMC6288228</ArticleId><ArticleId IdType="pubmed">30564580</ArticleId></ArticleIdList></Reference><Reference><Citation>Zare E.N., Khorsandi D., Zarepour A., Yilmaz H., Agarwal T., Hooshmand S., Mohammadinejad R., Ozdemir F., Sahin O., Adiguzel S. Biomedical applications of engineered heparin-based materials. Bioact. Mater. 2024;31:87–118. doi: 10.1016/j.bioactmat.2023.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bioactmat.2023.08.002</ArticleId><ArticleId IdType="pmc">PMC10440395</ArticleId><ArticleId IdType="pubmed">37609108</ArticleId></ArticleIdList></Reference><Reference><Citation>Meher M.K., Naidu G., Mishra A., Poluri K.M. A review on multifaceted biomedical applications of heparin nanocomposites: Progress and prospects. Int. J. Biol. Macromol. 2024;260:129379. doi: 10.1016/j.ijbiomac.2024.129379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2024.129379</ArticleId><ArticleId IdType="pubmed">38242410</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Torres M.d.P., Acosta-Torres L.S., Diaz-Torres L.A. Heparin-based nanoparticles: An overview of their applications. J. Nanomater. 2018;2018:1–8. doi: 10.1155/2018/9780489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/9780489</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar B.D., Balaraju M., Chandra J.S., Ghori S.S., Khan N.M., Ansari M.S., Emmanuel K.A., Murthy K. Heparin-based nanoparticles: A summary of their uses. Chelonian Res. Found. 2023;18:2290–2305. doi: 10.1155/2018/9780489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/9780489</ArticleId></ArticleIdList></Reference><Reference><Citation>Saurav S., Mohan A., Tabassum Z., Girdhar M. Recent trends in polymer-based nanocomposites and its application in bone tissue engineering. AIP Conf. Proc. 2024;2986:030138. doi: 10.1063/5.0197881.</Citation><ArticleIdList><ArticleId IdType="doi">10.1063/5.0197881</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemp M.M., Kumar A., Mousa S., Dyskin E., Yalcin M., Ajayan P., Linhardt R.J., Mousa S.A. Gold and silver nanoparticles conjugated with heparin derivative possess anti-angiogenesis properties. Nanotechnology. 2009;20:455104. doi: 10.1088/0957-4484/20/45/455104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1088/0957-4484/20/45/455104</ArticleId><ArticleId IdType="pubmed">19822927</ArticleId></ArticleIdList></Reference><Reference><Citation>Sultana R., Kamihira M. Bioengineered heparin: Advances in production technology. Biotechnol. Adv. 2024;77:108456. doi: 10.1016/j.biotechadv.2024.108456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biotechadv.2024.108456</ArticleId><ArticleId IdType="pubmed">39326809</ArticleId></ArticleIdList></Reference><Reference><Citation>Olczyk P., Mencner Ł., Komosinska-Vassev K. Diverse Roles of Heparan Sulfate and Heparin in Wound Repair. BioMed Res. Int. 2015;2015:549417. doi: 10.1155/2015/549417.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/549417</ArticleId><ArticleId IdType="pmc">PMC4508384</ArticleId><ArticleId IdType="pubmed">26236728</ArticleId></ArticleIdList></Reference><Reference><Citation>Casu B., Lindahl U. Structure and Biological Interactions of Heparin and Heparan Sulfate. Adv. Carbohydr. Chem. Biochem. 2001;57:159–206. doi: 10.1016/s0065-2318(01)57017-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0065-2318(01)57017-1</ArticleId><ArticleId IdType="pubmed">11836942</ArticleId></ArticleIdList></Reference><Reference><Citation>Onishi A., St Ange K., Dordick J.S., Linhardt R.J. Heparin and Anticoagulation. Front. Biosci. (Landmark Ed.) 2016;21:1372–1392. doi: 10.2741/4462.</Citation><ArticleIdList><ArticleId IdType="doi">10.2741/4462</ArticleId><ArticleId IdType="pubmed">27100512</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane D.A., Denton J., Flynn A.M., Thunberg L., Lindahl U. Anticoagulant Activities of Heparin Oligosaccharides and Their Neutralization by Platelet Factor 4. Biochem. J. 1984;218:725–732. doi: 10.1042/bj2180725.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/bj2180725</ArticleId><ArticleId IdType="pmc">PMC1153400</ArticleId><ArticleId IdType="pubmed">6721831</ArticleId></ArticleIdList></Reference><Reference><Citation>Oosta G.M., Gardner W.T., Beeler D.L., Rosenberg R.D. Multiple Functional Domains of the Heparin Molecule. Proc. Natl. Acad. Sci. USA. 1981;78:829–833. doi: 10.1073/pnas.78.2.829.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.78.2.829</ArticleId><ArticleId IdType="pmc">PMC319896</ArticleId><ArticleId IdType="pubmed">6940150</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezaie A.R. Calcium Enhances Heparin Catalysis of the Antithrombin-Factor Xa Reaction by a Template Mechanism: Evidence That Calcium Alleviates Gla Domain Antagonism of Heparin Binding to Factor Xa. J. Biol. Chem. 1998;273:16824–16827. doi: 10.1074/jbc.273.27.16824.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.273.27.16824</ArticleId><ArticleId IdType="pubmed">9642241</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin P.-H., Sinha U., Betz A. Antithrombin Binding of Low Molecular Weight Heparins and Inhibition of Factor Xa. Biochim. Biophys. Acta. 2001;1526:105–113. doi: 10.1016/S0304-4165(01)00117-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-4165(01)00117-9</ArticleId><ArticleId IdType="pubmed">11287128</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrowcliffe T.W., Le Shirley Y. The Effect of Calcium Chloride on Anti-Xa Activity of Heparin and Its Molecular Weight Fractions. Thromb. Haemost. 1989;62:950–954. doi: 10.1055/s-0038-1651034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0038-1651034</ArticleId><ArticleId IdType="pubmed">2556814</ArticleId></ArticleIdList></Reference><Reference><Citation>Huntington J.A. Shape-Shifting Serpins–Advantages of a Mobile Mechanism. Trends. Biochem. Sci. 2006;31:427–435. doi: 10.1016/j.tibs.2006.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tibs.2006.06.005</ArticleId><ArticleId IdType="pubmed">16820297</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson D.J.D., Langdown J., Huntington J.A. Molecular Basis of Factor IXa Recognition by Heparin-Activated Antithrombin Revealed by a 1.7-Å Structure of the Ternary Complex. Proc. Natl. Acad. Sci. USA. 2010;107:645–650. doi: 10.1073/pnas.0910144107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0910144107</ArticleId><ArticleId IdType="pmc">PMC2818950</ArticleId><ArticleId IdType="pubmed">20080729</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiebe E.M., Stafford A.R., Fredenburgh J.C., Weitz J.I. Mechanism of Catalysis of Inhibition of Factor IXa by Antithrombin in the Presence of Heparin or Pentasaccharide. J. Biol. Chem. 2003;278:35767–35774. doi: 10.1074/jbc.M304803200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M304803200</ArticleId><ArticleId IdType="pubmed">12832413</ArticleId></ArticleIdList></Reference><Reference><Citation>Gozzo A.J., Nunes V.A., Cruz-Silva I., Carmona A.K., Nader H.B., Faljoni-Alario A., Sampaio M.U., Araújo M.S. Heparin Modulation of Human Plasma Kallikrein on Different Substrates and Inhibitors. Biol. Chem. 2006;387:1129–1138. doi: 10.1515/BC.2006.139.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/BC.2006.139</ArticleId><ArticleId IdType="pubmed">16895484</ArticleId></ArticleIdList></Reference><Reference><Citation>Olson S.T., Swanson R., Raub-Segall E., Bedsted T., Sadri M., Petitou M., Hérault J.-P., Herbert J.-M., Björk I. Accelerating Ability of Synthetic Oligosaccharides on Antithrombin Inhibition of Proteinases of the Clotting and Fibrinolytic Systems Comparison with Heparin and Low-Molecular-Weight Heparin. Thromb. Haemost. 2004;92:929–939. doi: 10.1160/TH04-06-0384.</Citation><ArticleIdList><ArticleId IdType="doi">10.1160/TH04-06-0384</ArticleId><ArticleId IdType="pubmed">15543318</ArticleId></ArticleIdList></Reference><Reference><Citation>Martínez-Martínez I., Ordóñez A., Pedersen S., de la Morena-Barrio M.E., Navarro-Fernández J., Kristensen S.R., Miñano A., Padilla J., Vicente V., Corral J. Heparin Affinity of Factor VIIa: Implications on the Physiological Inhibition by Antithrombin and Clearance of Recombinant Factor VIIa. Thromb. Res. 2011;127:154–160. doi: 10.1016/j.thromres.2010.11.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2010.11.008</ArticleId><ArticleId IdType="pubmed">21126754</ArticleId></ArticleIdList></Reference><Reference><Citation>Petitou M., Hérault J.-P., Bernat A., Driguez P.-A., Duchaussoy P., Lormeau J.-C., Herbert J.-M. Synthesis of thrombin-inhibiting heparin mimetics without side effects. Nature. 1999;398:417–422. doi: 10.1038/18877.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/18877</ArticleId><ArticleId IdType="pubmed">10201371</ArticleId></ArticleIdList></Reference><Reference><Citation>Baráth M., Hansen S.U., Dalton C.E., Jayson G.C., Miller G.J., Gardiner J.M. Modular synthesis of heparin-related tetra-, hexa-and octasaccharides with differential O-6 protections: Programming for regiodefined 6-O-modifications. Molecules. 2015;20:6167–6180. doi: 10.3390/molecules20046167.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules20046167</ArticleId><ArticleId IdType="pmc">PMC4421873</ArticleId><ArticleId IdType="pubmed">25859776</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen S.U., Miller G.J., Cliff M.J., Jayson G.C., Gardiner J.M. Making the longest sugars: A chemical synthesis of heparin-related [4]n oligosaccharides from 16-mer to 40-mer. Chem. Sci. 2015;6:6158–6164. doi: 10.1039/C5SC02091C.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C5SC02091C</ArticleId><ArticleId IdType="pmc">PMC6054106</ArticleId><ArticleId IdType="pubmed">30090231</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy S., El Hadri A., Richard S., Denis F., Holte K., Duffner J., Yu F., Galcheva-Gargova Z., Capila I., Schultes B. Synthesis and biological evaluation of a unique heparin mimetic hexasaccharide for structure–activity relationship studies. J. Med. Chem. 2014;57:4511–4520. doi: 10.1021/jm4016069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm4016069</ArticleId><ArticleId IdType="pubmed">24786387</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu L.-D., Shie C.-R., Kulkarni S.S., Pan G.-R., Lu X.-A., Hung S.-C. Synthesis of 48 disaccharide building blocks for the assembly of a heparin and heparan sulfate oligosaccharide library. Org. Lett. 2006;8:5995–5998. doi: 10.1021/ol062464t.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ol062464t</ArticleId><ArticleId IdType="pubmed">17165913</ArticleId></ArticleIdList></Reference><Reference><Citation>Pawar N.J., Wang L., Higo T., Bhattacharya C., Kancharla P.K., Zhang F., Baryal K., Huo C., Liu J., Linhardt R.J. Expedient synthesis of core disaccharide building blocks from natural polysaccharides for heparan sulfate oligosaccharide assembly. Angew. Chem. Int. Ed. Eng. 2019;131:18750–18756. doi: 10.1002/ange.201908805.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ange.201908805</ArticleId><ArticleId IdType="pmc">PMC6901730</ArticleId><ArticleId IdType="pubmed">31553820</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramadan S., Su G., Baryal K., Hsieh-Wilson L.C., Liu J., Huang X. Automated solid phase assisted synthesis of a heparan sulfate disaccharide library. Org. Chem. Front. 2022;9:2910–2920. doi: 10.1039/D2QO00439A.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D2QO00439A</ArticleId><ArticleId IdType="pmc">PMC9536483</ArticleId><ArticleId IdType="pubmed">36212917</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Lin L., Huang H., Linhardt R.J. Chemoenzymatic synthesis of glycosaminoglycans. Acc. Chem. Res. 2019;53:335–346. doi: 10.1021/acs.accounts.9b00420.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.accounts.9b00420</ArticleId><ArticleId IdType="pubmed">31714740</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottschalk J., Elling L. Current state on the enzymatic synthesis of glycosaminoglycans. Curr. Opin. Chem. Biol. 2021;61:71–80. doi: 10.1016/j.cbpa.2020.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cbpa.2020.09.008</ArticleId><ArticleId IdType="pubmed">33271474</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindahl U., Li J., Kusche-Gullberg M., Salmivirta M., Alaranta S., Veromaa T., Emeis J., Roberts I., Taylor C., Oreste P. Generation of “Neoheparin” from E. coli K5 capsular polysaccharide. J. Med. Chem. 2005;48:349–352. doi: 10.1021/jm049812m.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm049812m</ArticleId><ArticleId IdType="pubmed">15658847</ArticleId></ArticleIdList></Reference><Reference><Citation>Casu B., Grazioli G., Razi N., Guerrini M., Naggi A., Torri G., Oreste P., Tursi F., Zoppetti G., Lindahl U. Heparin-like compounds prepared by chemical modification of capsular polysaccharide from E. coli K5. Carbohydr. Res. 1994;263:271–284. doi: 10.1016/0008-6215(94)00172-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0008-6215(94)00172-3</ArticleId><ArticleId IdType="pubmed">7805054</ArticleId></ArticleIdList></Reference><Reference><Citation>Datta P., Yan L., Awofiranye A., Dordick J.S., Linhardt R.J. Heparosan Chain Characterization: Sequential depolymerization of E. coli K5 heparosan by a bacterial eliminase heparin lyase iii and a bacterial hydrolase heparanase bp to prepare defined oligomers. Biotechnol. J. 2021;16:2000336. doi: 10.1002/biot.202000336.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/biot.202000336</ArticleId><ArticleId IdType="pubmed">33006278</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y., Masuko S., Takieddin M., Xu H., Liu R., Jing J., Mousa S.A., Linhardt R.J., Liu J. Chemoenzymatic Synthesis of Homogeneous Ultralow Molecular Weight Heparins. Science. 2011;334:498–501. doi: 10.1126/science.1207478.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1207478</ArticleId><ArticleId IdType="pmc">PMC3425363</ArticleId><ArticleId IdType="pubmed">22034431</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Linhardt R.J. Chemoenzymatic synthesis of heparan sulfate and heparin oligosaccharides and nmr analysis: Paving the way to a diverse library for glycobiologists. Nat. Prod. Rep. 2014;31:7932–7940. doi: 10.1039/C7SC03541A.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C7SC03541A</ArticleId><ArticleId IdType="pmc">PMC5849142</ArticleId><ArticleId IdType="pubmed">29568440</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y., Pempe E.H., Liu J. Chemoenzymatic synthesis of heparin oligosaccharides with both Anti-factor Xa and Anti-factor IIa activities. J. Biol. Chem. 2012;287:29054–29061. doi: 10.1074/jbc.M112.358523.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.358523</ArticleId><ArticleId IdType="pmc">PMC3436553</ArticleId><ArticleId IdType="pubmed">22773834</ArticleId></ArticleIdList></Reference><Reference><Citation>Zha Z., Liu Y., Miao Y., Liao S., Wang S.-Y., Tang H., Yin H. Preparation and characterization of 2-deacetyl-3-o-sulfo-heparosan and its antitumor effects via the fibroblast growth factor receptor pathway. Int. J. Biol. Macromol. 2022;201:47–58. doi: 10.1016/j.ijbiomac.2021.12.098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2021.12.098</ArticleId><ArticleId IdType="pubmed">34998873</ArticleId></ArticleIdList></Reference><Reference><Citation>Douaisi M., Paskaleva E.E., Fu L., Grover N., McManaman C.L., Varghese S., Brodfuehrer P.R., Gibson J.M., de Joode I., Xia K. Synthesis of bioengineered heparin chemically and biologically similar to porcine-derived products and convertible to low MW heparin. Proc. Natl. Acad. Sci. USA. 2024;121:e2315586121. doi: 10.1073/pnas.2315586121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2315586121</ArticleId><ArticleId IdType="pmc">PMC10998570</ArticleId><ArticleId IdType="pubmed">38498726</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng J.-Q., Li Y., Wang Y.-J., Cao Y.-L., Xin S.-Y., Li X.-Y., Xi R.-M., Wang F.-S., Sheng J.-Z. Biosynthetic production of anticoagulant heparin polysaccharides through metabolic and sulfotransferases engineering strategies. Nat. Commun. 2024;15:3755. doi: 10.1038/s41467-024-48193-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-024-48193-5</ArticleId><ArticleId IdType="pmc">PMC11069525</ArticleId><ArticleId IdType="pubmed">38704385</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L., Chopra P., Boons G. Chemoenzymatic synthesis of heparan sulfate oligosaccharides having a domain structure. Angew. Chem. 2022;134:e202211112. doi: 10.1002/ange.202211112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ange.202211112</ArticleId><ArticleId IdType="pmc">PMC9828060</ArticleId><ArticleId IdType="pubmed">36148891</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao S., Zhang T., Kan Y., Li H., Li J. Overview of the current procedures in synthesis of heparin saccharides. Carbohydr. Polym. 2024;339:122220. doi: 10.1016/j.carbpol.2024.122220.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.carbpol.2024.122220</ArticleId><ArticleId IdType="pubmed">38823902</ArticleId></ArticleIdList></Reference><Reference><Citation>Baik J.Y., Gasimli L., Yang B., Datta P., Zhang F., Glass C.A., Esko J.D., Linhardt R.J., Sharfstein S.T. Metabolic engineering of chinese hamster ovary cells: Towards a bioengineered heparin. Metab. Eng. 2012;14:81–90. doi: 10.1016/j.ymben.2012.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymben.2012.01.008</ArticleId><ArticleId IdType="pmc">PMC3299301</ArticleId><ArticleId IdType="pubmed">22326251</ArticleId></ArticleIdList></Reference><Reference><Citation>Baik J.Y., Wang C.L., Yang B., Linhardt R.J., Sharfstein S.T. Toward a bioengineered heparin: Challenges and strategies for metabolic engineering of mammalian cells. Bioengineered. 2012;3:227–231. doi: 10.4161/bioe.20902.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/bioe.20902</ArticleId><ArticleId IdType="pmc">PMC3476871</ArticleId><ArticleId IdType="pubmed">22714556</ArticleId></ArticleIdList></Reference><Reference><Citation>Datta P., Linhardt R.J., Sharfstein S.T. An’omics approach towards CHO cell engineering. Biotechnol. Bioeng. 2013;110:1255–1271. doi: 10.1002/bit.24841.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bit.24841</ArticleId><ArticleId IdType="pubmed">23322664</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Wang Y., Zhou Z., Wang P., Xi X., Hu S., Xu R., Du G., Li J., Chen J. Synthesis of bioengineered heparin by recombinant yeast Pichia pastoris. Green Chem. 2022;24:3180–3192. doi: 10.1039/D1GC04672A.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D1GC04672A</ArticleId></ArticleIdList></Reference><Reference><Citation>Cress B.F., Toparlak O.D., Guleria S., Lebovich M., Stieglitz J.T., Englaender J.A., Jones J.A., Linhardt R.J., Koffas M.A.G. CRISPathBrick: Modular combinatorial assembly of type II-A CRISPR arrays for dcas9-mediated multiplex transcriptional repression in E. coli. ACS Synth. Biol. 2015;4:987–1000. doi: 10.1021/acssynbio.5b00012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acssynbio.5b00012</ArticleId><ArticleId IdType="pubmed">25822415</ArticleId></ArticleIdList></Reference><Reference><Citation>Datta P., Li G., Yang B., Zhao X., Baik J.Y., Gemmill T.R., Sharfstein S.T., Linhardt R.J. Bioengineered chinese hamster ovary cells with Golgi-targeted 3-O-sulfotransferase-1 biosynthesize heparan sulfate with an antithrombin-binding site. J. Biol. Chem. 2013;288:37308–37318. doi: 10.1074/jbc.M113.519033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.519033</ArticleId><ArticleId IdType="pmc">PMC3873583</ArticleId><ArticleId IdType="pubmed">24247246</ArticleId></ArticleIdList></Reference><Reference><Citation>Leyh T.S., Taylor J.C., Markham G.D. The sulfate activation locus of Escherichia coli K12: Cloning, genetic, and enzymatic characterization. J. Biol. Chem. 1988;263:2409–2416. doi: 10.1016/S0021-9258(18)69222-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(18)69222-1</ArticleId><ArticleId IdType="pubmed">2828368</ArticleId></ArticleIdList></Reference><Reference><Citation>Higashi K., Hosoyama S., Ohno A., Masuko S., Yang B., Sterner E., Toida T. Photochemical preparation of a novel low molecular weight heparin. Carbohyd. Polym. 2012;87:1737–1743. doi: 10.1016/j.carbpol.2011.09.087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.carbpol.2011.09.087</ArticleId><ArticleId IdType="pmc">PMC3245882</ArticleId><ArticleId IdType="pubmed">22205826</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhi Z.J., Li J.H., Chen J.L., Li S., Cheng H., Liu D.H., Chen S.G. Preparation of low molecular weight heparin using an ultrasound-assisted Fentonsystem. Ultrason. Sonochem. 2019;52:184–192. doi: 10.1016/j.ultsonch.2018.11.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ultsonch.2018.11.016</ArticleId><ArticleId IdType="pmc">PMC6475493</ArticleId><ArticleId IdType="pubmed">30559077</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen X.M., Liu Z.F., Li J.H., Wu D.M., Zhu M., Yan L.F., Chen S.G. Development of low molecular weight heparin by H2O2/ascorbic acid with ultrasonic power and its anti-metastasis property. Int. J. Biol. Macromol. 2019;133:101–109. doi: 10.1016/j.ijbiomac.2019.04.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2019.04.019</ArticleId><ArticleId IdType="pubmed">30954594</ArticleId></ArticleIdList></Reference><Reference><Citation>Linhardt R.J., Liu J. Synthetic heparin. Curr. Opin. Pharmacol. 2012;12:217–219. doi: 10.1016/j.coph.2011.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coph.2011.12.002</ArticleId><ArticleId IdType="pmc">PMC3496756</ArticleId><ArticleId IdType="pubmed">22325855</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding Y., Prasad C.V.V., Bai H., Wang B. Efficient and practical synthesis of Fondaparinux. Bioorg. Med. Chem. Lett. 2017;27:2424–2427. doi: 10.1016/j.bmcl.2017.04.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2017.04.013</ArticleId><ArticleId IdType="pubmed">28408227</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X., Wang Q., Zhang A., Shao X., Liu T., Tang B., Fang G. Strategies for sustained release of heparin: A review. Carbohydr. Polym. 2022;294:119793. doi: 10.1016/j.carbpol.2022.119793.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.carbpol.2022.119793</ArticleId><ArticleId IdType="pubmed">35868762</ArticleId></ArticleIdList></Reference><Reference><Citation>Dey S., Lo H.J., Wong C.H. Programmable one-pot synthesis of heparin pentasaccharide fondaparinux. Org. Lett. 2020;22:4638–4642. doi: 10.1021/acs.orglett.0c01386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.orglett.0c01386</ArticleId><ArticleId IdType="pmc">PMC7347301</ArticleId><ArticleId IdType="pubmed">32496799</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin H., Chen Q., Zhang Y.Y., Hao K.F., Zhang G.Q., Zhao W. Preactivation-based, iterative one-pot synthesis of anticoagulant pentasaccharide fondaparinux sodium. Org. Chem. Front. 2019;6:3116–3120. doi: 10.1039/C9QO00480G.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C9QO00480G</ArticleId></ArticleIdList></Reference><Reference><Citation>Linhardt R.J., Toida T. Role of glycosaminoglycans in cellular communication. Acc. Chem. Res. 2004;37:431–438. doi: 10.1021/ar030138x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ar030138x</ArticleId><ArticleId IdType="pubmed">15260505</ArticleId></ArticleIdList></Reference><Reference><Citation>Mousavi S., Moradi M., Khorshidahmad T., Motamedi M. Anti-Inflammatory effects of heparin and its derivatives: A systematic review. Adv. Pharmacol. Pharm. Sci. 2015;2015:507151. doi: 10.1155/2015/507151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/507151</ArticleId><ArticleId IdType="pmc">PMC4443644</ArticleId><ArticleId IdType="pubmed">26064103</ArticleId></ArticleIdList></Reference><Reference><Citation>Poterucha T.J., Libby P., Goldhaber S.Z. More than an anticoagulant: Do heparins have direct anti-inflammatory effects? Thromb. Haemost. 2017;117:437–444. doi: 10.1160/TH16-08-0620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1160/TH16-08-0620</ArticleId><ArticleId IdType="pubmed">27975101</ArticleId></ArticleIdList></Reference><Reference><Citation>Severin I.C., Soares A., Hantson J., Teixeira M., Sachs D., Valognes D., Scheer A., Schwarz M.K., Wells T.N.C., Proudfoot A.E.I. Glycosaminoglycan analogs as a novel anti-inflammatory strategy. Front. Immunol. 2012;3:293. doi: 10.3389/fimmu.2012.00293.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2012.00293</ArticleId><ArticleId IdType="pmc">PMC3472544</ArticleId><ArticleId IdType="pubmed">23087686</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan Y., Ji Y., Su N., Mei X., Wang Y., Du S., Zhu W., Zhang C., Lu Y., Xing X.-H. Non-anticoagulant effects of low molecular weight heparins in inflammatory disorders: A review. Carbohydr. Polym. 2017;160:71–81. doi: 10.1016/j.carbpol.2016.12.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.carbpol.2016.12.037</ArticleId><ArticleId IdType="pubmed">28115102</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilotti A.C., Nimlamool W., Pugh R., Slee J.B., Barthol T.C., Miller E.A., Lowe-Krentz L.J. Heparin responses in vascular smooth muscle cells involve CGMP-dependent protein kinase (PKG) J. Cell. Physiol. 2014;229:2142–2152. doi: 10.1002/jcp.24677.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.24677</ArticleId><ArticleId IdType="pmc">PMC4149598</ArticleId><ArticleId IdType="pubmed">24911927</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumgart D.C. CB-01-05-MMX, a novel oral controlled-release low molecular weight heparin for the potential treatment of ulcerative colitis. Curr. Opin. Investig. Drugs. 2010;11:571–576.</Citation><ArticleIdList><ArticleId IdType="pubmed">20419603</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi L., Zhang X., Wang X. Heparin inhibits the inflammation and proliferation of human rheumatoid arthritis fibroblast-like synoviocytes through the NF-κB pathway. Mol. Med. Rep. 2016;14:3743–3748. doi: 10.3892/mmr.2016.5719.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2016.5719</ArticleId><ArticleId IdType="pubmed">27599556</ArticleId></ArticleIdList></Reference><Reference><Citation>Malhotra S., Bhasin D., Shafiq N., Pandhi P. Drug treatment of ulcerative colitis: Unfractionated heparin, low molecular weight heparins and beyond. Expert Opin. Pharmacother. 2004;5:329–334. doi: 10.1517/14656566.5.2.329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14656566.5.2.329</ArticleId><ArticleId IdType="pubmed">14996629</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelaty N., Abd-Elsalam M. Allergy. Volume 62. Blackwell Publishing; Oxford, UK: 2007. Efficacy of inhaled heparin is effective in the treatment of acute exacerbation of asthma; p. 216.</Citation></Reference><Reference><Citation>Bendstrup K.E., Jensen J.I. Inhaled heparin is effective in exacerbations of asthma. Respir. Med. 2000;94:174–175. doi: 10.1053/rmed.1999.0677.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/rmed.1999.0677</ArticleId><ArticleId IdType="pubmed">10714425</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghonim M.A., Wang J., Ibba S.V., Luu H.H., Pyakurel K., Benslimane I., Mousa S., Boulares A.H. Sulfated non-anticoagulant heparin blocks Th2-induced asthma by modulating the IL-4/signal transducer and activator of transcription 6/janus kinase 1 pathway. J. Transl. Med. 2018;16:243. doi: 10.1186/s12967-018-1621-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-018-1621-5</ArticleId><ArticleId IdType="pmc">PMC6119587</ArticleId><ArticleId IdType="pubmed">30172259</ArticleId></ArticleIdList></Reference><Reference><Citation>Shute J.K., Puxeddu E., Calzetta L. Therapeutic use of heparin and derivatives beyond anticoagulation in patients with bronchial asthma or COPD. Curr. Opin. Pharmacol. 2018;40:39–45. doi: 10.1016/j.coph.2018.01.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coph.2018.01.006</ArticleId><ArticleId IdType="pubmed">29455115</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai X., Wang K., Wang J., Zheng Y., Hu W. Effects of low molecular weight heparin calcium combined with insulin on immune function, inflammatory response, haemorheology and coagulation in patients with high triglyceride acute pancreatitis. Acta Medica Mediterr. 2020;36:1557–1561. doi: 10.19193/0393-6384_2020_3_243.</Citation><ArticleIdList><ArticleId IdType="doi">10.19193/0393-6384_2020_3_243</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceranowicz P., Dembinski A., Warzecha Z., Dembinski M., Cieszkowski J., Rembisz K., Konturek S.J., Kusnierz-Cabala B., Tomaszewska R., Pawlik W.W. Protective and therapeutic effect of heparin in acute pancreatitis. J. Physiol. Pharmacol. 2008;59:103–125.</Citation><ArticleIdList><ArticleId IdType="pubmed">18955758</ArticleId></ArticleIdList></Reference><Reference><Citation>Granell S., Gironella M., Bulbena O., Panés J., Mauri M., Sabater L., Aparisi L., Gelpí E., Closa D. Heparin mobilizes xanthine oxidase and induces lung inflammation in acute pancreatitis. Crit. Care Med. 2003;31:525–530. doi: 10.1097/01.CCM.0000049948.64660.06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000049948.64660.06</ArticleId><ArticleId IdType="pubmed">12576961</ArticleId></ArticleIdList></Reference><Reference><Citation>Shute J.K. Heparin, Low molecular weight heparin, and non-anticoagulant derivatives for the treatment of inflammatory lung disease. Pharmaceuticals. 2023;16:584. doi: 10.3390/ph16040584.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph16040584</ArticleId><ArticleId IdType="pmc">PMC10141002</ArticleId><ArticleId IdType="pubmed">37111341</ArticleId></ArticleIdList></Reference><Reference><Citation>Fath M.A., Wu X., Hileman R.E., Linhardt R.J., Kashem M.A., Nelson R.M., Wright C.D., Abraham W.M. Interaction of secretory leukocyte protease inhibitor with heparin inhibits proteases involved in asthma. J. Biol. Chem. 1998;273:13563–13569. doi: 10.1074/jbc.273.22.13563.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.273.22.13563</ArticleId><ArticleId IdType="pubmed">9593692</ArticleId></ArticleIdList></Reference><Reference><Citation>Derhaschnig U., Pernerstorfer T., Knechtelsdorfer M., Hollenstein U., Panzer S., Jilma B. Evaluation of antiinflammatory and antiadhesive effects of heparins in human endotoxemia. Crit. Care Med. 2003;31:1108–1112. doi: 10.1097/01.CCM.0000059441.70680.DC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000059441.70680.DC</ArticleId><ArticleId IdType="pubmed">12682480</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Ma X. The role of heparin in sepsis: Much more than just an anticoagulant. Br. J. Haematol. 2017;179:389–398. doi: 10.1111/bjh.14885.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.14885</ArticleId><ArticleId IdType="pubmed">28832958</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L., Ling Y., Huang M., Yin T., Gou S.-M., Zhan N.-Y., Xiong J.-X., Wu H.-S., Yang Z.-Y., Wang C.-Y. Heparin inhibits the inflammatory response induced by LPS and HMGB1 by blocking the binding of HMGB1 to the surface of macrophages. Cytokine. 2015;72:36–42. doi: 10.1016/j.cyto.2014.12.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2014.12.010</ArticleId><ArticleId IdType="pubmed">25562836</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Y., Wang X., Li Z., He Z., Yang X., Cheng X., Peng Y., Xue Q., Bai Y., Zhang R. Heparin prevents caspase-11-dependent septic lethality independent of anticoagulant properties. Immunity. 2021;54:454–467. doi: 10.1016/j.immuni.2021.01.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.01.007</ArticleId><ArticleId IdType="pubmed">33561388</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogwood J., Pitchford S., Mulloy B., Page C., Gray E. Heparin and non-anticoagulant heparin attenuate histone-induced inflammatory responses in whole blood. PLoS ONE. 2020;15:e0233644. doi: 10.1371/journal.pone.0233644.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0233644</ArticleId><ArticleId IdType="pmc">PMC7259574</ArticleId><ArticleId IdType="pubmed">32469940</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang T., Liu L., Voglmeir J. Chemoenzymatic synthesis of ultralow and low-molecular weight heparins. Biochim. Biophys. Acta Proteins Proteom. 2020;1868:140301. doi: 10.1016/j.bbapap.2019.140301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbapap.2019.140301</ArticleId><ArticleId IdType="pubmed">31678194</ArticleId></ArticleIdList></Reference><Reference><Citation>Wildhagen K.C.A.A., García de Frutos P., Reutelingsperger C.P., Schrijver R., Aresté C., Ortega-Gómez A., Deckers N.M., Hemker H.C., Soehnlein O., Nicolaes G.A.F. Nonanticoagulant heparin prevents histone-mediated cytotoxicity in vitro and improves survival in sepsis. Blood. 2014;123:1098–1101. doi: 10.1182/blood-2013-07-514984.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2013-07-514984</ArticleId><ArticleId IdType="pubmed">24264231</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Han X., Xia K., Xu Y., Yang Y., Oshima K., Haeger S.M., Perez M.J., McMurtry S.A., Hippensteel J.A. Circulating heparin oligosaccharides rapidly target the hippocampus in sepsis, potentially impacting cognitive functions. Proc. Natl. Acad. Sci. USA. 2019;116:9208–9213. doi: 10.1073/pnas.1902227116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1902227116</ArticleId><ArticleId IdType="pmc">PMC6511061</ArticleId><ArticleId IdType="pubmed">31010931</ArticleId></ArticleIdList></Reference><Reference><Citation>Yini S., Heng Z., Xin A., Xiaochun M. Effect of unfractionated heparin on endothelial glycocalyx in a septic shock model. Acta Anaesthesiol. Scand. 2015;59:160–169. doi: 10.1111/aas.12418.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/aas.12418</ArticleId><ArticleId IdType="pubmed">25312742</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Liu Z., Luo M., Xi Y., Li C., Wang S., Yang R. Therapeutic effect of low-molecular-weight heparin on adult sepsis: A meta-analysis. Ann. Palliat. Med. 2021;10:3113127–3115127. doi: 10.21037/apm-21-169.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/apm-21-169</ArticleId><ArticleId IdType="pubmed">33849098</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu S., Yu S., Wang L., Ma X., Li X. Unfractionated Heparin Improves the Clinical Efficacy in Adult Sepsis Patients: A Systematic Review and Meta-Analysis. BMC Anesthesiol. 2022;22:28. doi: 10.1186/s12871-021-01545-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12871-021-01545-w</ArticleId><ArticleId IdType="pmc">PMC8777179</ArticleId><ArticleId IdType="pubmed">35062871</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyriakoulis K.G., Kollias A., Kyriakoulis I.G., Kyprianou I.A., Papachrysostomou C., Makaronis P., Kotronias R.A., Terentes-Printzios D., Toskas I., Mikhailidis D.P. Thromboprophylaxis in patients with COVID-19: Systematic review of national and international clinical guidance reports. Curr. Vasc. Pharmacol. 2022;20:96–110. doi: 10.2174/1570161119666210824160332.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1570161119666210824160332</ArticleId><ArticleId IdType="pubmed">34431465</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J. Thromb. Haemost. 2020;18:844–847. doi: 10.1111/jth.14768.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14768</ArticleId><ArticleId IdType="pmc">PMC7166509</ArticleId><ArticleId IdType="pubmed">32073213</ArticleId></ArticleIdList></Reference><Reference><Citation>Poli D., Antonucci E., Ageno W., Prandoni P., Palareti G., Marcucci R. Low in-hospital mortality rate in patients with COVID-19 receiving thromboprophylaxis: Data from the multicentre observational START-COVID register. Intern. Emerg. Med. 2022;17:1013–1021. doi: 10.1007/s11739-021-02891-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11739-021-02891-w</ArticleId><ArticleId IdType="pmc">PMC8720160</ArticleId><ArticleId IdType="pubmed">34973126</ArticleId></ArticleIdList></Reference><Reference><Citation>van Haren F.M.P., van Loon L.M., Steins A., Smoot T.L., Sas C., Staas S., Vilaseca A.B., Barbera R.A., Vidmar G., Beccari H. Inhaled nebulised unfractionated heparin for the treatment of hospitalised patients with COVID-19: A multicentre case series of 98 patients. Br. J. Clin. Pharmacol. 2022;88:2802–2813. doi: 10.1111/bcp.15212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.15212</ArticleId><ArticleId IdType="pubmed">34984714</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhai Z., Kan Q., Li W., Qin X., Qu J., Shi Y., Xu R., Xu Y., Zhang Z., Wang C. VTE Risk Profiles and Prophylaxis in medical and surgical inpatients: The identification of chinese hospitalized patients’ risk profile for venous thromboembolism (DissolVE-2)—A cross-sectional study. Chest. 2019;155:114–122. doi: 10.1016/j.chest.2018.09.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2018.09.020</ArticleId><ArticleId IdType="pubmed">30300652</ArticleId></ArticleIdList></Reference><Reference><Citation>Rentsch C.T., Beckman J.A., Tomlinson L., Gellad W.F., Alcorn C., Kidwai-Khan F., Skanderson M., Brittain E., King J.T., Ho Y.-L. Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: Cohort study. BMJ. 2021;372:n311. doi: 10.1136/bmj.n311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n311</ArticleId><ArticleId IdType="pmc">PMC7876672</ArticleId><ArticleId IdType="pubmed">33574135</ArticleId></ArticleIdList></Reference><Reference><Citation>Thachil J., Tang N., Gando S., Falanga A., Cattaneo M., Levi M., Clark C., Iba T. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J. Thromb. Haemost. 2020;18:1023–1026. doi: 10.1111/jth.14810.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14810</ArticleId><ArticleId IdType="pmc">PMC9906133</ArticleId><ArticleId IdType="pubmed">32338827</ArticleId></ArticleIdList></Reference><Reference><Citation>Clausen T.M., Sandoval D.R., Spliid C.B., Pihl J., Perrett H.R., Painter C.D., Narayanan A., Majowicz S.A., Kwong E.M., McVicar R.N. SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2. Cell. 2020;183:1043–1057. doi: 10.1016/j.cell.2020.09.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.033</ArticleId><ArticleId IdType="pmc">PMC7489987</ArticleId><ArticleId IdType="pubmed">32970989</ArticleId></ArticleIdList></Reference><Reference><Citation>Mycroft-West C.J., Su D., Pagani I., Rudd T.R., Elli S., Gandhi N.S., Guimond S.E., Miller G.J., Meneghetti M.C.Z., Nader H.B. Heparin inhibits cellular invasion by SARS-CoV-2: Structural dependence of the interaction of the spike S1 receptor-binding domain with heparin. Thromb. Haemost. 2020;120:1700–1715. doi: 10.1055/s-0040-1721319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0040-1721319</ArticleId><ArticleId IdType="pmc">PMC7869224</ArticleId><ArticleId IdType="pubmed">33368089</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q., Chen C.Z., Swaroop M., Xu M., Wang L., Lee J., Wang A.Q., Pradhan M., Hagen N., Chen L. Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro. Cell Discov. 2020;6:80. doi: 10.1038/s41421-020-00222-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41421-020-00222-5</ArticleId><ArticleId IdType="pmc">PMC7610239</ArticleId><ArticleId IdType="pubmed">33298900</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Zhang Y., Pang H., Li S.J. Heparin interacts with the main protease of SARS-CoV-2 and inhibits its activity. Spectrochim. Acta Part A Mol. Biomol. Spectrosc. 2022;267:120595. doi: 10.1016/j.saa.2021.120595.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.saa.2021.120595</ArticleId><ArticleId IdType="pmc">PMC8591854</ArticleId><ArticleId IdType="pubmed">34815178</ArticleId></ArticleIdList></Reference><Reference><Citation>Cron R.Q., Goyal G., Chatham W.W. Cytokine storm syndrome. Annu. Rev. Med. 2023;74:321–337. doi: 10.1146/annurev-med-042921-112837.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-med-042921-112837</ArticleId><ArticleId IdType="pubmed">36228171</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu X. Potential of heparin in the treatment of COVID-19–associated myocarditis. Pediatr. Emerg. Care. 2022;38:e504. doi: 10.1097/PEC.0000000000002645.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PEC.0000000000002645</ArticleId><ArticleId IdType="pmc">PMC8808758</ArticleId><ArticleId IdType="pubmed">35100755</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue M., Zeng Y., Qu H.-Q., Zhang T., Li N., Huang H., Zheng P., Hu H., Zhou L., Duan Z. Heparin-binding protein levels correlate with aggravation and multiorgan damage in severe COVID-19. ERJ Open Res. 2021;7:00741–02020. doi: 10.1183/23120541.00741-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/23120541.00741-2020</ArticleId><ArticleId IdType="pmc">PMC7667727</ArticleId><ArticleId IdType="pubmed">33564671</ArticleId></ArticleIdList></Reference><Reference><Citation>Copeland R., Balasubramaniam A., Tiwari V., Zhang F., Bridges A., Linhardt R.J., Shukla D., Liu J. Using a 3-O-sulfated heparin octasaccharide to inhibit the entry of Herpes Simplex Virus Type 1. Biochemistry. 2008;47:5774–5783. doi: 10.1021/bi800205t.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi800205t</ArticleId><ArticleId IdType="pmc">PMC2504729</ArticleId><ArticleId IdType="pubmed">18457417</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y.-L., Lei H.-Y., Lin Y.-S., Yeh T.-M., Chen S.-H., Liu H.-S. Heparin inhibits dengue-2 virus infection of five human liver cell lines. Antiviral Res. 2002;56:93–96. doi: 10.1016/S0166-3542(02)00095-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0166-3542(02)00095-5</ArticleId><ArticleId IdType="pubmed">12323403</ArticleId></ArticleIdList></Reference><Reference><Citation>Angeletti P.C. Seeing HPV in the new light offers a glimpse of heparin. Structure. 2017;25:213. doi: 10.1016/j.str.2017.01.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.str.2017.01.009</ArticleId><ArticleId IdType="pubmed">28178455</ArticleId></ArticleIdList></Reference><Reference><Citation>Nassar R.A., Browne E.P., Chen J., Klibanov A.M. Removing Human Immunodeficiency Virus (HIV) from human blood using immobilized heparin. Biotechnol. Lett. 2012;34:853–856. doi: 10.1007/s10529-011-0840-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10529-011-0840-0</ArticleId><ArticleId IdType="pubmed">22207147</ArticleId></ArticleIdList></Reference><Reference><Citation>Plochmann K., Horn A., Gschmack E., Armbruster N., Krieg J., Wiktorowicz T., Weber C., Stirnnagel K., Lindemann D., Rethwilm A. Heparan sulfate is an attachment factor for foamy virus entry. J. Virol. 2012;86:10028–10035. doi: 10.1128/JVI.00051-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00051-12</ArticleId><ArticleId IdType="pmc">PMC3446549</ArticleId><ArticleId IdType="pubmed">22787203</ArticleId></ArticleIdList></Reference><Reference><Citation>Urbinati C., Milanesi M., Lauro N., Bertelli C., David G., D’Ursi P., Rusnati M., Chiodelli P. HIV-1 tat and heparan sulfate proteoglycans orchestrate the setup of in cis and in trans cell-surface interactions functional to lymphocyte trans-endothelial migration. Molecules. 2021;26:7488. doi: 10.3390/molecules26247488.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules26247488</ArticleId><ArticleId IdType="pmc">PMC8705413</ArticleId><ArticleId IdType="pubmed">34946571</ArticleId></ArticleIdList></Reference><Reference><Citation>Skidmore M.A., Kajaste-Rudnitski A., Wells N.M., Guimond S.E., Rudd T.R., Yates E.A., Vicenzi E. Inhibition of influenza H5N1 invasion by modified heparin derivatives. Med. Chem. Commun. 2015;6:640–646. doi: 10.1039/C4MD00516C.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C4MD00516C</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghezzi S., Cooper L., Rubio A., Pagani I., Capobianchi M.R., Ippolito G., Pelletier J., Meneghetti M.C.Z., Lima M.A., Skidmore M.A. Heparin prevents Zika virus induced-cytopathic effects in human neural progenitor cells. Antiviral Res. 2017;140:13–17. doi: 10.1016/j.antiviral.2016.12.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2016.12.023</ArticleId><ArticleId IdType="pmc">PMC7113768</ArticleId><ArticleId IdType="pubmed">28063994</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S.Y., Koetzner C.A., Payne A.F., Nierode G.J., Yu Y., Wang R., Barr E., Dordick J.S., Kramer L.D., Zhang F. Glycosaminoglycan compositional analysis of relevant tissues in Zika virus pathogenesis and in vitro evaluation of heparin as an antiviral against Zika Virus infection. Biochemistry. 2019;58:1155–1166. doi: 10.1021/acs.biochem.8b01267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.biochem.8b01267</ArticleId><ArticleId IdType="pmc">PMC7686953</ArticleId><ArticleId IdType="pubmed">30698412</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S.Y., Zhao J., Liu X., Fraser K., Lin L., Zhang X., Zhang F., Dordick J.S., Linhardt R.J. Interaction of Zika virus envelope protein with glycosaminoglycans. Biochemistry. 2017;56:1151–1162. doi: 10.1021/acs.biochem.6b01056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.biochem.6b01056</ArticleId><ArticleId IdType="pmc">PMC7579681</ArticleId><ArticleId IdType="pubmed">28151637</ArticleId></ArticleIdList></Reference><Reference><Citation>Abreu R., Essler L., Loy A., Quinn F., Giri P. Heparin inhibits intracellular Mycobacterium tuberculosis bacterial replication by reducing iron levels in human macrophages. Sci. Rep. 2018;8:7296. doi: 10.1038/s41598-018-25480-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-25480-y</ArticleId><ArticleId IdType="pmc">PMC5940867</ArticleId><ArticleId IdType="pubmed">29740038</ArticleId></ArticleIdList></Reference><Reference><Citation>Hills F.A., Abrahams V.M., González-Timón B., Francis J., Cloke B., Hinkson L., Rai R., Mor G., Regan L., Sullivan M. Heparin prevents programmed cell death in human trophoblast. Mol. Hum. Reprod. 2006;12:237–243. doi: 10.1093/molehr/gal026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/molehr/gal026</ArticleId><ArticleId IdType="pubmed">16556679</ArticleId></ArticleIdList></Reference><Reference><Citation>Leitgeb A.M., Blomqvist K., Cho-Ngwa F., Samje M., Nde P., Titanji V., Wahlgren M. Low Anticoagulant heparin disrupts Plasmodium falciparum rosettes in fresh clinical isolates. Am. J. Trop. Med. Hyg. 2011;84:390. doi: 10.4269/ajtmh.2011.10-0256.</Citation><ArticleIdList><ArticleId IdType="doi">10.4269/ajtmh.2011.10-0256</ArticleId><ArticleId IdType="pmc">PMC3042813</ArticleId><ArticleId IdType="pubmed">21363975</ArticleId></ArticleIdList></Reference><Reference><Citation>Marques J., Moles E., Urbán P., Prohens R., Busquets M.A., Sevrin C., Grandfils C., Fernàndez-Busquets X. Application of heparin as a dual agent with antimalarial and liposome targeting activities toward plasmodium-infected red blood cells. Nanomedicine. 2014;10:1719–1728. doi: 10.1016/j.nano.2014.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nano.2014.06.002</ArticleId><ArticleId IdType="pubmed">24941466</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinnis P., Coppi A., Toida T., Toyoda H., Kinoshita-Toyoda A., Xie J., Kemp M.M., Linhardt R.J. Mosquito heparan sulfate and its potential role in malaria infection and transmission. J. Biol. Chem. 2007;282:25376–25384. doi: 10.1074/jbc.M704698200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M704698200</ArticleId><ArticleId IdType="pmc">PMC2121605</ArticleId><ArticleId IdType="pubmed">17597060</ArticleId></ArticleIdList></Reference><Reference><Citation>San Anselmo M., Lantero E., Avalos-Padilla Y., Bouzón-Arnáiz I., Ramírez M., Postigo A., Serrano J.L., Sierra T., Hernández-Ainsa S., Fernàndez-Busquets X. Heparin-coated dendronized hyperbranched polymers for antimalarial targeted delivery. ACS Appl. Polym. Mater. 2022;5:381–390. doi: 10.1021/acsapm.2c01553.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsapm.2c01553</ArticleId><ArticleId IdType="pmc">PMC9844211</ArticleId><ArticleId IdType="pubmed">36686062</ArticleId></ArticleIdList></Reference><Reference><Citation>Steere A.C., Strle F., Wormser G.P., Hu L.T., Branda J.A., Hovius J.W.R., Li X., Mead P.S. Lyme borreliosis. Nat. Rev. Dis. Primers. 2016;2:16090. doi: 10.1038/nrdp.2016.90.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2016.90</ArticleId><ArticleId IdType="pmc">PMC5539539</ArticleId><ArticleId IdType="pubmed">27976670</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y.-P., Yu Y., Marcinkiewicz A.L., Lederman P., Hart T.M., Zhang F., Linhardt R.J. Non-anticoagulant heparin as a pre-exposure prophylaxis prevents lyme disease infection. ACS Infect. Dis. 2020;6:503–514. doi: 10.1021/acsinfecdis.9b00425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsinfecdis.9b00425</ArticleId><ArticleId IdType="pmc">PMC7241291</ArticleId><ArticleId IdType="pubmed">31961652</ArticleId></ArticleIdList></Reference><Reference><Citation>Axelsson J., Ferreira M., Adolfsson L., McCrea K., Ward R., Larm O. Cytokines in blood from septic patients interact with surface-immobilized heparin. ASAIO J. 2010;56:48–51. doi: 10.1097/MAT.0b013e3181c3fec8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MAT.0b013e3181c3fec8</ArticleId><ArticleId IdType="pubmed">20071911</ArticleId></ArticleIdList></Reference><Reference><Citation>Buitrago-Pabón A.L., Ruiz-Sáenz S., Jiménez-Alberto A., Aparicio-Ozores G., Castelán-Vega J.A., Ribas-Aparicio R.M. An update on Zika virus vaccine development and new research approaches. Microbiol. Res. 2024;15:667–692. doi: 10.3390/microbiolres15020044.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microbiolres15020044</ArticleId></ArticleIdList></Reference><Reference><Citation>Goubran H.A., Burnouf T., Radosevic M., El-Ekiaby M. The platelet–cancer loop. Eur. J. Intern. Med. 2013;24:393–400. doi: 10.1016/j.ejim.2013.01.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejim.2013.01.017</ArticleId><ArticleId IdType="pubmed">23433737</ArticleId></ArticleIdList></Reference><Reference><Citation>Metharom P., Falasca M., Berndt M.C. The history of Armand Trousseau and cancer-associated thrombosis. Cancers. 2019;11:158. doi: 10.3390/cancers11020158.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers11020158</ArticleId><ArticleId IdType="pmc">PMC6406548</ArticleId><ArticleId IdType="pubmed">30708967</ArticleId></ArticleIdList></Reference><Reference><Citation>Gervaso L., Dave H., Khorana A.A. Venous and arterial thromboembolism in patients with cancer: JACC: CardioOncology state-of-the-art review. JACC CardioOncol. 2021;3:173–190. doi: 10.1016/j.jaccao.2021.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaccao.2021.03.001</ArticleId><ArticleId IdType="pmc">PMC8352228</ArticleId><ArticleId IdType="pubmed">34396323</ArticleId></ArticleIdList></Reference><Reference><Citation>Cosmi B. An update on the efficacy and safety of novel anticoagulants for cancer associated thrombosis. Expert Opin. Pharmacother. 2021;22:583–594. doi: 10.1080/14656566.2020.1847273.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14656566.2020.1847273</ArticleId><ArticleId IdType="pubmed">33243038</ArticleId></ArticleIdList></Reference><Reference><Citation>Smorenburg S.M., Van Noorden C.J.F. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol. Rev. 2001;53:93–106.</Citation><ArticleIdList><ArticleId IdType="pubmed">11171940</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma S.-N., Mao Z.-X., Wu Y., Liang M.-X., Wang D.-D., Chen X., Chang P., Zhang W., Tang J.-H. The anti-cancer properties of heparin and its derivatives: A review and prospect. Cell Adhes. Migr. 2020;14:118–128. doi: 10.1080/19336918.2020.1767489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19336918.2020.1767489</ArticleId><ArticleId IdType="pmc">PMC7513850</ArticleId><ArticleId IdType="pubmed">32538273</ArticleId></ArticleIdList></Reference><Reference><Citation>Falanga A., Marchetti M. Cancer-associated thrombosis: Enhanced awareness and pathophysiologic complexity. J. Thromb. Haemost. 2023;21:1397–1408. doi: 10.1016/j.jtha.2023.02.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtha.2023.02.029</ArticleId><ArticleId IdType="pubmed">36931602</ArticleId></ArticleIdList></Reference><Reference><Citation>Coombe D.R., Gandhi N.S. Heparanase: A challenging cancer drug target. Front. Oncol. 2019;9:1316. doi: 10.3389/fonc.2019.01316.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2019.01316</ArticleId><ArticleId IdType="pmc">PMC6892829</ArticleId><ArticleId IdType="pubmed">31850210</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur R., Deb P.K., Diwan V., Saini B. Heparanase inhibitors in cancer progression: Recent advances. Curr. Pharm. Des. 2021;27:43–68. doi: 10.2174/1381612826666201113105250.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1381612826666201113105250</ArticleId><ArticleId IdType="pubmed">33185156</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindahl U., Li J.-P. Heparanase—Discovery and targets. Adv. Exp. Med. Biol. 2020;1221:61–69. doi: 10.1007/978-3-030-34521-1_2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-030-34521-1_2</ArticleId><ArticleId IdType="pubmed">32274706</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlodavsky I., Abboud-Jarrous G., Elkin M., Naggi A., Casu B., Sasisekharan R., Ilan N. The impact of heparanese and heparin on cancer metastasis and angiogenesis. Pathophysiol. Haemost. Thromb. 2006;35:116–127. doi: 10.1159/000093553.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000093553</ArticleId><ArticleId IdType="pubmed">16855356</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanzi C., Zaffaroni N., Cassinelli G. Targeting heparan sulfate proteoglycans and their modifying enzymes to enhance anticancer chemotherapy efficacy and overcome drug resistance. Curr. Med. Chem. 2017;24:2860–2886. doi: 10.2174/0929867324666170216114248.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867324666170216114248</ArticleId><ArticleId IdType="pubmed">28215163</ArticleId></ArticleIdList></Reference><Reference><Citation>Kilarski W.W., Bikfalvi A. Recent developments in tumor angiogenesis. Curr. Pharm. Biotechnol. 2007;8:3–9. doi: 10.2174/138920107779941444.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/138920107779941444</ArticleId><ArticleId IdType="pubmed">17311548</ArticleId></ArticleIdList></Reference><Reference><Citation>Duckworth C.A., Guimond S.E., Sindrewicz P., Hughes A.J., French N.S., Lian L.-Y., Yates E.A., Pritchard D.M., Rhodes J.M., Turnbull J.E. Chemically modified, non-anticoagulant heparin derivatives are potent galectin-3 binding inhibitors and inhibit circulating galectin-3-promoted metastasis. Oncotarget. 2015;6:23671. doi: 10.18632/oncotarget.4409.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.4409</ArticleId><ArticleId IdType="pmc">PMC4695144</ArticleId><ArticleId IdType="pubmed">26160844</ArticleId></ArticleIdList></Reference><Reference><Citation>Atallah J., Khachfe H.H., Berro J., Assi H.I. The use of heparin and heparin-like molecules in cancer treatment: A review. Cancer Treat. Res. Commun. 2020;24:100192. doi: 10.1016/j.ctarc.2020.100192.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ctarc.2020.100192</ArticleId><ArticleId IdType="pubmed">32673846</ArticleId></ArticleIdList></Reference><Reference><Citation>Ek L., Gezelius E., Bergman B., Bendahl P.O., Anderson H., Sundberg J., Wallberg M., Falkmer U., Verma S., Belting M. Randomized Phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: The RASTEN trial. Ann. Oncol. 2018;29:398–404. doi: 10.1093/annonc/mdx716.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mdx716</ArticleId><ArticleId IdType="pmc">PMC5834130</ArticleId><ArticleId IdType="pubmed">29106448</ArticleId></ArticleIdList></Reference><Reference><Citation>Gezelius E., Bendahl P.O., de Oliveira K.G., Ek L., Bergman B., Sundberg J., Strandberg K., Krämer R., Belting M. Low-molecular-weight heparin adherence and effects on survival within a randomised phase III lung cancer trial (RASTEN) Eur. J. Cancer. 2019;118:82–90. doi: 10.1016/j.ejca.2019.06.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejca.2019.06.015</ArticleId><ArticleId IdType="pubmed">31326730</ArticleId></ArticleIdList></Reference><Reference><Citation>O’Reilly E.M., Mahalingam D., Roach J.M., Miller P.J., Rosano M.E., Krause S., Avery W., Bekaii-Saab T.S., Shao S.H., Richards D.A., et al. Necuparanib combined with nab-paclitaxel+ gemcitabine in patients with metastatic pancreatic cancer: Phase 2 results. J. Clin. Oncol. 2017;35:370. doi: 10.1200/JCO.2017.35.4_suppl.370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2017.35.4_suppl.370</ArticleId><ArticleId IdType="pmc">PMC5728039</ArticleId><ArticleId IdType="pubmed">29158367</ArticleId></ArticleIdList></Reference><Reference><Citation>Chhabra M., Wilson J.C., Wu L., Davies G.J., Gandhi N.S., Ferro V. Structural insights into Pixatimod (PG545) inhibition of heparanase, a key enzyme in cancer and viral infections. Chemistry. 2022;28:e202104222. doi: 10.1002/chem.202104222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/chem.202104222</ArticleId><ArticleId IdType="pmc">PMC9303737</ArticleId><ArticleId IdType="pubmed">34981584</ArticleId></ArticleIdList></Reference><Reference><Citation>Dredge K., Brennan T.V., Hammond E., Lickliter J.D., Lin L., Bampton D., Handley P., Lankesheer F., Morrish G., Yang Y. A Phase I study of the novel immunomodulatory agent PG545 (Pixatimod) in subjects with advanced solid tumours. Br. J. Cancer. 2018;118:1035–1041. doi: 10.1038/s41416-018-0006-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41416-018-0006-0</ArticleId><ArticleId IdType="pmc">PMC5931096</ArticleId><ArticleId IdType="pubmed">29531325</ArticleId></ArticleIdList></Reference><Reference><Citation>Khorana A.A., McCrae K.R., Milentijevic D., Fortier J., Nelson W.W., Laliberté F., Crivera C., Lefebvre P., Yannicelli D., Schein J. Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis. Res. Pract. Thromb. Haemost. 2017;1:14–22. doi: 10.1002/rth2.12002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rth2.12002</ArticleId><ArticleId IdType="pmc">PMC6058198</ArticleId><ArticleId IdType="pubmed">30046670</ArticleId></ArticleIdList></Reference><Reference><Citation>Young A.M., Marshall A., Thirlwall J., Chapman O., Lokare A., Hill C., Hale D., Dunn J.A., Lyman G.H., Hutchinson C. Comparison of an oral factor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: Results of a randomized trial (SELECT-D) J. Clin. Oncol. 2018;36:2017–2023. doi: 10.1200/JCO.2018.78.8034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2018.78.8034</ArticleId><ArticleId IdType="pubmed">29746227</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrag D., Uno H., Rosovsky R., Rutherford C., Sanfilippo K., Villano J.L., Drescher M., Jayaram N., Holmes C., Feldman L. Direct oral anticoagulants vs low-molecular-weight heparin and recurrent vte in patients with cancer: A randomized clinical trial. JAMA. 2023;329:1924–1933. doi: 10.1001/jama.2023.7843.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.7843</ArticleId><ArticleId IdType="pmc">PMC10265290</ArticleId><ArticleId IdType="pubmed">37266947</ArticleId></ArticleIdList></Reference><Reference><Citation>Planquette B., Bertoletti L., Charles-Nelson A., Laporte S., Grange C., Mahé I., Pernod G., Elias A., Couturaud F., Falvo N. Rivaroxaban vs Dalteparin in cancer-associated thromboembolism: A randomized trial. Chest. 2022;161:781–790. doi: 10.1016/j.chest.2021.09.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2021.09.037</ArticleId><ArticleId IdType="pubmed">34627853</ArticleId></ArticleIdList></Reference><Reference><Citation>McBane R.D., Wysokinski W.E., Le-Rademacher J.G., Zemla T., Ashrani A., Tafur A., Perepu U., Anderson D., Gundabolu K., Kuzma C. Apixaban and Dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE Trial. J. Thromb. Haemost. 2020;14662:411–421. doi: 10.1111/jth.14662.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14662</ArticleId><ArticleId IdType="pubmed">31630479</ArticleId></ArticleIdList></Reference><Reference><Citation>Agnelli G., Becattini C., Meyer G., Muñoz A., Huisman M.V., Connors J.M., Cohen A., Bauersachs R., Brenner B., Torbicki A. Apixaban for the treatment of venous thromboembolism associated with cancer. N. Engl. J. Med. 2020;382:1599–1607. doi: 10.1056/NEJMoa1915103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1915103</ArticleId><ArticleId IdType="pubmed">32223112</ArticleId></ArticleIdList></Reference><Reference><Citation>Raskob G.E., Van Es N., Verhamme P., Carrier M., Di Nisio M., Garcia D., Grosso M.A., Kakkar A.K., Kovacs M.J., Mercuri M.F. Edoxaban for the treatment of cancer-associated venous thromboembolism. N. Engl. J. Med. 2018;378:615–624. doi: 10.1056/NEJMoa1711948.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1711948</ArticleId><ArticleId IdType="pubmed">29231094</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou H., Chen T.-T., Ye L., Ma J.-J., Zhang J.-H. Efficacy and safety of direct oral anticoagulants versus low-molecular-weight heparin for thromboprophylaxis after cancer surgery: A systematic review and meta-analysis. World J. Surg. Oncol. 2024;22:69. doi: 10.1186/s12957-024-03341-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12957-024-03341-5</ArticleId><ArticleId IdType="pmc">PMC10895850</ArticleId><ArticleId IdType="pubmed">38403630</ArticleId></ArticleIdList></Reference><Reference><Citation>Frackiewicz A., Kalaska B., Miklosz J., Mogielnicki A. The methods for removal of direct oral anticoagulants and heparins to improve the monitoring of hemostasis: A narrative literature review. Thromb. J. 2023;21:58. doi: 10.1186/s12959-023-00501-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12959-023-00501-7</ArticleId><ArticleId IdType="pmc">PMC10197842</ArticleId><ArticleId IdType="pubmed">37208753</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamed S., Coombe D.R. Heparin mimetics: Their therapeutic potential. Pharmaceuticals. 2017;10:78. doi: 10.3390/ph10040078.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph10040078</ArticleId><ArticleId IdType="pmc">PMC5748635</ArticleId><ArticleId IdType="pubmed">28974047</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshikawa N., Nakanishi K., Sako M., Oba M.S., Mori R., Ota E., Ishikura K., Hataya H., Honda M., Ito S. A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment. Kidney Int. 2015;87:225–232. doi: 10.1038/ki.2014.260.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.2014.260</ArticleId><ArticleId IdType="pmc">PMC4284810</ArticleId><ArticleId IdType="pubmed">25054775</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha A., Saha A., Kumar M., Sharma S., Afzal K., Mehta A., Kalaivani M., Hari P., Bagga A. Extending initial prednisolone treatment in a randomized control trial from 3 to 6 months did not significantly influence the course of illness in children with steroid-sensitive nephrotic syndrome. Kidney Int. 2015;87:217–224. doi: 10.1038/ki.2014.240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.2014.240</ArticleId><ArticleId IdType="pubmed">25029428</ArticleId></ArticleIdList></Reference><Reference><Citation>Muso E., Mune M., Hirano T., Hattori M., Kimura K., Watanabe T., Yokoyama H., Sato H., Uchida S., Wada T. Immediate Therapeutic efficacy of low-density lipoprotein apheresis for drug-resistant nephrotic syndrome: Evidence from the short-term results from the POLARIS Study. Clin. Exp. Nephrol. 2015;19:379–386. doi: 10.1007/s10157-014-0996-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10157-014-0996-8</ArticleId><ArticleId IdType="pubmed">24934117</ArticleId></ArticleIdList></Reference><Reference><Citation>Medjeral-Thomas N., Ziaj S., Condon M., Galliford J., Levy J., Cairns T., Griffith M. Retrospective analysis of a novel regimen for the prevention of venous thromboembolism in nephrotic syndrome. Clin. J. Am. Soc. Nephrol. 2014;9:478–483. doi: 10.2215/CJN.07190713.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.07190713</ArticleId><ArticleId IdType="pmc">PMC3944768</ArticleId><ArticleId IdType="pubmed">24334865</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y., Yang X., Zeng H., Lu W., Fang Y. Effects of low molecular weight heparin combined with prednisone on coagulation and kidney function of pediatricwith nephrotic syndrome. Int. J. Clin. Exp. Med. 2019;12:6032–6037.</Citation></Reference><Reference><Citation>Li R., Xing J., Mu X., Wang H., Zhang L., Zhao Y., Zhang Y. Sulodexide therapy for the treatment of diabetic nephropathy, a meta-analysis and literature review. Drug Des. Devel. Ther. 2015;9:6275–6283. doi: 10.2147/DDDT.S87973.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DDDT.S87973</ArticleId><ArticleId IdType="pmc">PMC4671764</ArticleId><ArticleId IdType="pubmed">26664049</ArticleId></ArticleIdList></Reference><Reference><Citation>Stopschinski B.E., Thomas T.L., Nadji S., Darvish E., Fan L., Holmes B.B., Modi A.R., Finnell J.G., Kashmer O.M., Estill-Terpack S. A synthetic heparinoid blocks tau aggregate cell uptake and amplification. J. Biol. Chem. 2020;295:2974–2983. doi: 10.1074/jbc.RA119.010353.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA119.010353</ArticleId><ArticleId IdType="pmc">PMC7062170</ArticleId><ArticleId IdType="pubmed">31974166</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanjanwala D., Londhe V., Trivedi R., Bonde S., Sawarkar S., Kale V., Patravale V. Polysaccharide-based hydrogels for medical devices, implants and tissue engineering: A review. Int. J. Biol. Macromol. 2024;256:128488. doi: 10.1016/j.ijbiomac.2023.128488.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2023.128488</ArticleId><ArticleId IdType="pubmed">38043653</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis E.J., Xu X. Abnormal glomerular permeability characteristics in diabetic nephropathy: Implications for the therapeutic use of low–molecular weight heparin. Diabetes Care. 2008;31:S202–S207. doi: 10.2337/dc08-s251.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc08-s251</ArticleId><ArticleId IdType="pubmed">18227486</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbadi A., Loftis J., Wang A., Yu M., Wang Y., Shakya S., Li X., Maytin E., Hascall V. Heparin inhibits proinflammatory and promotes anti-inflammatory macrophage polarization under hyperglycemic stress. J. Biol. Chem. 2020;295:4849–4857. doi: 10.1074/jbc.RA119.012419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA119.012419</ArticleId><ArticleId IdType="pmc">PMC7152777</ArticleId><ArticleId IdType="pubmed">32107314</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang A., Ren J., Wang C.P., Hascall V.C. Heparin prevents intracellular hyaluronan synthesis and autophagy responses in hyperglycemic dividing mesangial cells and activates synthesis of an extensive extracellular monocyte-adhesive hyaluronan matrix after completing cell division. J. Biol. Chem. 2014;289:9418–9429. doi: 10.1074/jbc.M113.541441.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.541441</ArticleId><ArticleId IdType="pmc">PMC3979390</ArticleId><ArticleId IdType="pubmed">24482224</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceol M., Gambaro G., Sauer U., Baggio B., Anglani F., Forino M., Facchin S., Bordin L., Weigert C., Nerlich A. Glycosaminoglycan therapy prevents TGF-Β1 overexpression and pathologic changes in renal tissue of long-term diabetic rats. J. Am. Soc. Nephrol. 2000;11:2324–2336. doi: 10.1681/ASN.V11122324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.V11122324</ArticleId><ArticleId IdType="pubmed">11095655</ArticleId></ArticleIdList></Reference><Reference><Citation>Myint K.-M., Yamamoto Y., Doi T., Kato I., Harashima A., Yonekura H., Watanabe T., Shinohara H., Takeuchi M., Tsuneyama K. RAGE Control of diabetic nephropathy in a mouse model: Effects of rage gene disruption and administration of low–molecular weight heparin. Diabetes. 2006;55:2510–2522. doi: 10.2337/db06-0221.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db06-0221</ArticleId><ArticleId IdType="pubmed">16936199</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto H., Watanabe T., Yamamoto Y., Yonekura H., Munesue S., Harashima A., Ooe K., Hossain S., Saito H., Murakami N. RAGE in diabetic nephropathy. Curr. Mol. Med. 2007;7:752–757. doi: 10.2174/156652407783220769.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156652407783220769</ArticleId><ArticleId IdType="pubmed">18331233</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y. Observation of curative effect of fushen decoction combined with low molecular weight heparin on nephritis with anaphylactic purpura of heat-wet stasis syndrome in children. Mod. J. Integr. Tradit. Chin. West. Med. 2016;25:3562–3565+3569.</Citation></Reference><Reference><Citation>Chen J.-Y., Mao J.-H. Henoch-Schönlein purpura nephritis in children: Incidence, pathogenesis and management. World J. Pediatr. 2015;11:29–34. doi: 10.1007/s12519-014-0534-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12519-014-0534-5</ArticleId><ArticleId IdType="pubmed">25557596</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Lei M.F.W.J. Anticoagulant effect of low molecular weight heparin in hemodialysis treatment of acute renal failure. China Pract. Med. 2019;14:119–120.</Citation></Reference><Reference><Citation>Wong S.S.-M., Lau W.-Y., Chan P.-K., Wan C.-K., Cheng Y.-L. Low-molecular weight heparin infusion as anticoagulation for haemodialysis. Clin. Kidney J. 2016;9:630–635. doi: 10.1093/ckj/sfw049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ckj/sfw049</ArticleId><ArticleId IdType="pmc">PMC4957725</ArticleId><ArticleId IdType="pubmed">27478610</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo J.W.S.J., Zhong G.Y.S.X. Guidelines for rational drug use in coronary heart disease (Second Ed.) Chin. J. Front. Med. Sci. (Electron. Ed.) 2018;10:1–130.</Citation></Reference><Reference><Citation>Ibanez B., James S., Agewall S., Antunes M.J., Bucciarelli-Ducci C., Bueno H., Caforio A.L.P., Crea F., Goudevenos J.A., Halvorsen S. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with st-segment elevation: The task force for the management of acute myocardial infarction in patients presenting with st-segment elevation of the european society of cardiology (ESC) Eur. Heart J. 2018;39:119–177. doi: 10.1093/eurheartj/ehx393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehx393</ArticleId><ArticleId IdType="pubmed">28886621</ArticleId></ArticleIdList></Reference><Reference><Citation>Guidelines for rational use of thrombolytic therapy in patients with acute ST segment elevation myocardial infarction (Second Ed.) Chin. J. Front. Med. Sci. (Electron. Ed.) 2019;11:40–65.</Citation></Reference><Reference><Citation>Eikelboom J.W., Anand S.S., Malmberg K., Weitz J.I., Ginsberg J.S., Yusuf S. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without st elevation: A Meta-Analysis. Lancet. 2000;355:1936–1942. doi: 10.1016/S0140-6736(00)02324-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(00)02324-2</ArticleId><ArticleId IdType="pubmed">10859038</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen M., Mahaffey K.W., Pieper K., Pollack C.V., Antman E.M., Hoekstra J., Goodman S.G., Langer A., Col J.J., White H.D. A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the sYNERGY Trial: Enoxaparin versus unfractionated heparin in Non–ST-Segment elevation acute coronary syndromes. J. Am. Coll. Cardiol. 2006;48:1346–1354. doi: 10.1016/j.jacc.2006.05.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2006.05.058</ArticleId><ArticleId IdType="pubmed">17010793</ArticleId></ArticleIdList></Reference><Reference><Citation>Bikdeli B., Erlinge D., Valgimigli M., Kastrati A., Han Y., Steg P.G., Stables R.H., Mehran R., James S.K., Frigoli E. Bivalirudin versus heparin during PCI in NSTEMI: Individual patient data meta-analysis of large randomized trials. Circulation. 2023;148:1207–1219. doi: 10.1161/CIRCULATIONAHA.123.063946.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.123.063946</ArticleId><ArticleId IdType="pubmed">37746717</ArticleId></ArticleIdList></Reference><Reference><Citation>Erlinge D., Omerovic E., Fröbert O., Linder R., Danielewicz M., Hamid M., Swahn E., Henareh L., Wagner H., Hårdhammar P. Bivalirudin versus Heparin monotherapy in myocardial infarction. N. Engl. J. Med. 2017;377:1132–1142. doi: 10.1056/NEJMoa1706443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1706443</ArticleId><ArticleId IdType="pubmed">28844201</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel H., Garris R., Bhutani S., Shah P., Rampal U., Vasudev R., Melki G., Ghalyoun B.A., Virk H., Bikkina M. Bivalirudin versus heparin during percutaneous coronary intervention in patients with acute myocardial infarction. Cardiol. Res. 2019;10:278. doi: 10.14740/cr921.</Citation><ArticleIdList><ArticleId IdType="doi">10.14740/cr921</ArticleId><ArticleId IdType="pmc">PMC6785291</ArticleId><ArticleId IdType="pubmed">31636795</ArticleId></ArticleIdList></Reference><Reference><Citation>Centurión O.A. Heparin versus bivalirudin in acute myocardial infarction: Unfractionated heparin monotherapy elevated to primary treatment in contemporary percutaneous coronary intervention. Open Cardiovasc. Med. J. 2016;10:122. doi: 10.2174/1874192401610010122.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1874192401610010122</ArticleId><ArticleId IdType="pmc">PMC5002443</ArticleId><ArticleId IdType="pubmed">27583038</ArticleId></ArticleIdList></Reference><Reference><Citation>Deharo P., Johnson T.W., Rahbi H., Kandan R., Bowles R., Mozid A., Dorman S., Strange J.W., Baumbach A. Bivalirudin versus heparin in primary pci: Clinical outcomes and cost analysis. Open Heart. 2018;5:e000767. doi: 10.1136/openhrt-2017-000767.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/openhrt-2017-000767</ArticleId><ArticleId IdType="pmc">PMC5950626</ArticleId><ArticleId IdType="pubmed">29765614</ArticleId></ArticleIdList></Reference><Reference><Citation>Rashid M.K., Singh K., Bernick J., Wells G.A., Hibbert B., Russo J., So D.Y., Le May M.R. Periprocedural bivalirudin versus unfractionated heparin during percutaneous coronary intervention following fibrinolysis for ST-Segment elevation myocardial infarction. J. Invasive Cardiol. 2019;31:E387–E391.</Citation><ArticleIdList><ArticleId IdType="pubmed">31786531</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Abdouh A., Mhanna M., Jabri A., Madanat L., Alhuneafat L., Mostafa M.R., Kundu A., Gupta V. Bivalirudin versus unfractionated heparin in patients with myocardial infarction undergoing percutaneous coronary intervention: A systematic review and meta-analysis of randomized controlled trials. Cardiovasc. Revasc. Med. 2024;61:52–61. doi: 10.1016/j.carrev.2023.10.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.carrev.2023.10.014</ArticleId><ArticleId IdType="pubmed">37872022</ArticleId></ArticleIdList></Reference><Reference><Citation>Capodanno D., Gargiulo G., Capranzano P., Mehran R., Tamburino C., Stone G.W. Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary PCI: An updated meta-analysis of 10,350 patients from five randomized clinical trials. Eur. Heart J. Acute Cardiovasc. Care. 2016;5:253–262. doi: 10.1177/2048872615572599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2048872615572599</ArticleId><ArticleId IdType="pubmed">25746943</ArticleId></ArticleIdList></Reference><Reference><Citation>Collet J.-P., Thiele H. The ‘Ten Commandments’ for the 2020 ESC Guidelines for the Management of Acute coronary syndromes in patients presenting without persistent ST-segment elevation 2020. Eur. Heart J. 2020;41:3495–3497. doi: 10.1093/eurheartj/ehaa624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa624</ArticleId><ArticleId IdType="pubmed">33085966</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergamaschini L., Rossi E., Vergani C., De Simoni M.G. Alzheimer’s disease: Another target for heparin therapy. Sci. World J. 2009;9:891–908. doi: 10.1100/tsw.2009.100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1100/tsw.2009.100</ArticleId><ArticleId IdType="pmc">PMC5823143</ArticleId><ArticleId IdType="pubmed">19734963</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Q., Cornelli U., Hanin I., Jeske W.P., Linhardt R.J., Walenga J.M., Fareed J., Lee J.M. Heparin oligosaccharides as potential therapeutic agents in senile dementia. Curr. Pharm. Des. 2007;13:1607–1616. doi: 10.2174/138161207780765918.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/138161207780765918</ArticleId><ArticleId IdType="pmc">PMC4114250</ArticleId><ArticleId IdType="pubmed">17504153</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman D.S., Amieva H., Petersen R.C., Chételat G., Holtzman D.M., Hyman B.T., Nixon R.A., Jones D.T. Alzheimer disease. Nat. Rev. Dis. Primers. 2021;7:33. doi: 10.1038/s41572-021-00269-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-021-00269-y</ArticleId><ArticleId IdType="pmc">PMC8574196</ArticleId><ArticleId IdType="pubmed">33986301</ArticleId></ArticleIdList></Reference><Reference><Citation>Snow A.D., Cummings J.A., Lake T. The unifying hypothesis of Alzheimer’s Disease: Heparan sulfate proteoglycans/glycosaminoglycans are key as first hypothesized over 30 years ago. Front. Aging Neurosci. 2021;13:710683. doi: 10.3389/fnagi.2021.710683.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2021.710683</ArticleId><ArticleId IdType="pmc">PMC8521200</ArticleId><ArticleId IdType="pubmed">34671250</ArticleId></ArticleIdList></Reference><Reference><Citation>Timmer N.M., van Dijk L., van der Zee C.E.E.M., Kiliaan A., de Waal R.M.W., Verbeek M.M. Enoxaparin treatment administered at both early and late stages of amyloid β deposition improves cognition of APPswe/PS1dE9 mice with differential effects on brain Aβ Levels. Neurobiol. Dis. 2010;40:340–347. doi: 10.1016/j.nbd.2010.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2010.06.008</ArticleId><ArticleId IdType="pubmed">20600909</ArticleId></ArticleIdList></Reference><Reference><Citation>Leveugle B., Ding W., Laurence F., Dehouck M., Scanameo A., Cecchelli R., Fillit H. Heparin oligosaccharides that pass the blood-brain barrier inhibit β-amyloid precursor protein secretion and heparin binding to Β-Amyloid peptide. J. Neurochem. 1998;70:736–744. doi: 10.1046/j.1471-4159.1998.70020736.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1998.70020736.x</ArticleId><ArticleId IdType="pubmed">9453569</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J., Zhu Y., Song X., Xiao Y., Su G., Liu X., Wang Z., Xu Y., Liu J., Eliezer D. 3-O-Sulfation of heparan sulfate enhances tau interaction and cellular uptake. Angew. Chem. Int. Ed. 2020;59:1818–1827. doi: 10.1002/anie.201913029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.201913029</ArticleId><ArticleId IdType="pmc">PMC6982596</ArticleId><ArticleId IdType="pubmed">31692167</ArticleId></ArticleIdList></Reference><Reference><Citation>Mycroft-West C.J., Devlin A.J., Cooper L.C., Guimond S.E., Procter P., Guerrini M., Miller G.J., Fernig D.G., Yates E.A., Lima M.A. Glycosaminoglycans from litopenaeus vannamei inhibit the Alzheimer’s disease β Secretase, BACE1. Mar. Drugs. 2021;19:203. doi: 10.3390/md19040203.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/md19040203</ArticleId><ArticleId IdType="pmc">PMC8067017</ArticleId><ArticleId IdType="pubmed">33916819</ArticleId></ArticleIdList></Reference><Reference><Citation>Mycroft-West C.J., Cooper L.C., Devlin A.J., Procter P., Guimond S.E., Guerrini M., Fernig D.G., Lima M.A., Yates E.A., Skidmore M.A. A Glycosaminoglycan extract from portunus pelagicus inhibits BACE1, the β Secretase Implicated in Alzheimer’s Disease. Mar. Drugs. 2019;17:293. doi: 10.3390/md17050293.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/md17050293</ArticleId><ArticleId IdType="pmc">PMC6562973</ArticleId><ArticleId IdType="pubmed">31100859</ArticleId></ArticleIdList></Reference><Reference><Citation>Mycroft-West C.J., Devlin A.J., Cooper L.C., Procter P., Miller G.J., Fernig D.G., Guerrini M., Guimond S.E., Lima M.A., Yates E.A. Inhibition of BACE1, the β-Secretase implicated in Alzheimer’s Disease, by a chondroitin sulfate extract from Sardina pilchardus. Neural Regen. Res. 2020;15:1546–1553. doi: 10.4103/1673-5374.274341.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.274341</ArticleId><ArticleId IdType="pmc">PMC7059579</ArticleId><ArticleId IdType="pubmed">31997821</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z., Patel V.N., Song X., Xu Y., Kaminski A.M., Doan V.U., Su G., Liao Y., Mah D., Zhang F. Increased 3-O-Sulfated Heparan Sulfate in Alzheimer’s Disease Brain Is Associated with Genetic Risk Gene HS3ST1. Sci. Adv. 2023;9:eadf6232. doi: 10.1126/sciadv.adf6232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.adf6232</ArticleId><ArticleId IdType="pmc">PMC10219595</ArticleId><ArticleId IdType="pubmed">37235665</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin H.-W., Hong S.-W., Youn Y.C. Clinical aspects of the differential diagnosis of Parkinson’s Disease and parkinsonism. J. Clin. Neurol. 2022;18:259. doi: 10.3988/jcn.2022.18.3.259.</Citation><ArticleIdList><ArticleId IdType="doi">10.3988/jcn.2022.18.3.259</ArticleId><ArticleId IdType="pmc">PMC9163948</ArticleId><ArticleId IdType="pubmed">35589315</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Bu C., Wang H., Zhang B., Chen Q., Shi D., Chi L. Distinct mechanisms underlying the therapeutic effects of low-molecular-weight heparin and chondroitin sulfate on Parkinson’s Disease. Int. J. Biol. Macromol. 2024;262:129846. doi: 10.1016/j.ijbiomac.2024.129846.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2024.129846</ArticleId><ArticleId IdType="pubmed">38296150</ArticleId></ArticleIdList></Reference><Reference><Citation>Falanga A., Marchetti M., Vignoli A. Coagulation and cancer: Biological and clinical aspects. J. Thromb. Haemost. 2013;11:223–233. doi: 10.1111/jth.12075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.12075</ArticleId><ArticleId IdType="pubmed">23279708</ArticleId></ArticleIdList></Reference><Reference><Citation>Ejaz U., Akhtar F., Xue J., Wan X., Zhang T., He S. Inhibitory potential of low molecular weight heparin in cell adhesion; emphasis on tumor metastasis. Eur. J. Pharmacol. 2021;892:173778. doi: 10.1016/j.ejphar.2020.173778.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2020.173778</ArticleId><ArticleId IdType="pubmed">33271153</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu H., Luo Y., Xu D., Ke X., Ci T. Low molecular weight heparin modified bone targeting liposomes for orthotopic osteosarcoma and breast cancer bone metastatic tumors. Int. J. Biol. Macromol. 2020;164:2583–2597. doi: 10.1016/j.ijbiomac.2020.08.068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2020.08.068</ArticleId><ArticleId IdType="pubmed">32795579</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Du Q., Zou Y., Guo Q., Huang J., Tao L., Shen X., Peng J. Co-delivery of doxorubicin and epacadostat via heparin coated ph-sensitive liposomes to suppress the lung metastasis of melanoma. Int. J. Pharm. 2020;584:119446. doi: 10.1016/j.ijpharm.2020.119446.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2020.119446</ArticleId><ArticleId IdType="pubmed">32439586</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao D., Li H., Luo Y., Feng N., Ci T. Heparin modified photosensitizer-loaded liposomes for tumor treatment and alleviating metastasis in phototherapy. Int. J. Biol. Macromol. 2021;168:526–536. doi: 10.1016/j.ijbiomac.2020.12.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2020.12.043</ArticleId><ArticleId IdType="pubmed">33310104</ArticleId></ArticleIdList></Reference><Reference><Citation>Mei L., Liu Y., Zhang H., Zhang Z., Gao H., He Q. Antitumor and antimetastasis activities of heparin-based micelle served as both carrier and drug. ACS Appl. Mater. Interfaces. 2016;8:9577–9589. doi: 10.1021/acsami.5b12347.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsami.5b12347</ArticleId><ArticleId IdType="pubmed">27058058</ArticleId></ArticleIdList></Reference><Reference><Citation>Du X., Zhang Y., Zhang Y., Gao S., Yang X., Ye L., Zhai G. Cancer cell membrane camouflaged biomimetic nanosheets for enhanced chemo-photothermal-starvation therapy and tumor microenvironment remodeling. Appl. Mater. Today. 2022;29:101677. doi: 10.1016/j.apmt.2022.101677.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apmt.2022.101677</ArticleId></ArticleIdList></Reference><Reference><Citation>Erpenbeck L., Schön M.P. Deadly Allies: The fatal interplay between platelets and metastasizing cancer cells. Blood. 2010;115:3427–3436. doi: 10.1182/blood-2009-10-247296.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2009-10-247296</ArticleId><ArticleId IdType="pmc">PMC2867258</ArticleId><ArticleId IdType="pubmed">20194899</ArticleId></ArticleIdList></Reference><Reference><Citation>Norrby K. Low-molecular-weight heparins and angiogenesis. Apmis. 2006;114:79–102. doi: 10.1111/j.1600-0463.2006.apm_235.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0463.2006.apm_235.x</ArticleId><ArticleId IdType="pubmed">16519745</ArticleId></ArticleIdList></Reference><Reference><Citation>Akl M.R., Nagpal P., Ayoub N.M., Tai B., Prabhu S.A., Capac C.M., Gliksman M., Goy A., Suh K.S. Molecular and clinical significance of fibroblast growth factor 2 (FGF2/BFGF) in malignancies of solid and hematological cancers for personalized therapies. Oncotarget. 2016;7:44735. doi: 10.18632/oncotarget.8203.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.8203</ArticleId><ArticleId IdType="pmc">PMC5190132</ArticleId><ArticleId IdType="pubmed">27007053</ArticleId></ArticleIdList></Reference><Reference><Citation>Knaack S., Lode A., Hoyer B., Rösen-Wolff A., Gabrielyan A., Roeder I., Gelinsky M. Heparin Modification of a biomimetic bone matrix for controlled release of VEGF. J. Biomed. Mater. Res. Part A. 2014;102:3500–3511. doi: 10.1002/jbm.a.35020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jbm.a.35020</ArticleId><ArticleId IdType="pubmed">24178515</ArticleId></ArticleIdList></Reference><Reference><Citation>Nawaz A., Zaman Safi S., Sikandar S., Zeeshan R., Zulfiqar S., Mehmood N., Alobaid H.M., Rehman F., Imran M., Tariq M. Heparin-loaded alginate hydrogels: Characterization and molecular mechanisms of their angiogenic and anti-microbial potential. Materials. 2022;15:6683. doi: 10.3390/ma15196683.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ma15196683</ArticleId><ArticleId IdType="pmc">PMC9573464</ArticleId><ArticleId IdType="pubmed">36234025</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Yang Y., Zhang Y., Huang M., Zhou Z., Luo W., Tang J., Wang J., Xiao Q., Chen H. Dual-targeting heparin-based nanoparticles that re-assemble in blood for glioma therapy through both anti-proliferation and anti-angiogenesis. Adv. Funct. Mater. 2016;26:7873–7885. doi: 10.1002/adfm.201602810.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adfm.201602810</ArticleId></ArticleIdList></Reference><Reference><Citation>Nourreddine F.Z., Oussedik-Oumehdi H., Laraba-Djebari F. Myotoxicity induced by cerastes cerastes venom: Beneficial effect of heparin in skeletal muscle tissue regeneration. Acta Trop. 2020;202:105274. doi: 10.1016/j.actatropica.2019.105274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.actatropica.2019.105274</ArticleId><ArticleId IdType="pubmed">31738878</ArticleId></ArticleIdList></Reference><Reference><Citation>Saliba M.J., Jr. Heparin in the treatment of burns: A review. Burns. 2001;27:349–358. doi: 10.1016/S0305-4179(00)00130-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0305-4179(00)00130-3</ArticleId><ArticleId IdType="pubmed">11348743</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye Y., Zhou Y., Jing Z., Xu Y., Yin D. Electrospun heparin-loaded nano-fiber sutures for the amelioration of achilles tendon rupture regeneration: In vivo evaluation. J. Mater. Chem. B. 2021;9:4154–4168. doi: 10.1039/D1TB00162K.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D1TB00162K</ArticleId><ArticleId IdType="pubmed">33982044</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K., Zhao G. An effective wound healing material based on gold incorporation into a heparin-polyvinyl alcohol nanocomposite: Enhanced in vitro and in vivo care of perioperative period. J. Clust. Sci. 2022;33:1655–1665. doi: 10.1007/s10876-021-02078-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10876-021-02078-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulati K., Meher M.K., Poluri K.M. Glycosaminoglycan-based resorbable polymer composites in tissue refurbishment. Regen. Med. 2017;12:431–457. doi: 10.2217/rme-2017-0012.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/rme-2017-0012</ArticleId><ArticleId IdType="pubmed">28621207</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Y., Kiick K.L. Heparin-functionalized polymeric biomaterials in tissue engineering and drug delivery applications. Acta Biomater. 2014;10:1588–1600. doi: 10.1016/j.actbio.2013.07.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.actbio.2013.07.031</ArticleId><ArticleId IdType="pmc">PMC3937301</ArticleId><ArticleId IdType="pubmed">23911941</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan B., Wang M. Customized Ca–P/PHBV Nanocomposite scaffolds for bone tissue engineering: Design, fabrication, surface modification and sustained release of growth factor. J. R. Soc. Interface. 2010;7:S615–S629. doi: 10.1098/rsif.2010.0127.focus.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rsif.2010.0127.focus</ArticleId><ArticleId IdType="pmc">PMC3024573</ArticleId><ArticleId IdType="pubmed">20504805</ArticleId></ArticleIdList></Reference><Reference><Citation>Conzelmann C., Müller J.A., Perkhofer L., Sparrer K.M.J., Zelikin A.N., Münch J., Kleger A. Inhaled and systemic heparin as a repurposed direct antiviral drug for prevention and treatment of COVID-19. Clin. Med. 2020;20:e218. doi: 10.7861/clinmed.2020-0351.</Citation><ArticleIdList><ArticleId IdType="doi">10.7861/clinmed.2020-0351</ArticleId><ArticleId IdType="pmc">PMC7687307</ArticleId><ArticleId IdType="pubmed">32863274</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludwig R.J. Therapeutic use of heparin beyond anticoagulation. Curr. Drug Discov. Technol. 2009;6:281–289. doi: 10.2174/157016309789869001.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/157016309789869001</ArticleId><ArticleId IdType="pubmed">20025596</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaferani A., Talsma D., Richter M.K.S., Daha M.R., Navis G.J., Seelen M.A., van den Born J. Heparin/heparan sulphate interactions with complement—A possible target for reduction of renal function loss? Nephrol. Dial. Transplant. 2014;29:515–522. doi: 10.1093/ndt/gft243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gft243</ArticleId><ArticleId IdType="pubmed">23880790</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Li L., Shi Y., Yu S., Ma X. Different signaling pathways involved in the anti-inflammatory effects of unfractionated heparin on lipopolysaccharide-stimulated human endothelial cells. J. Inflamm. 2020;17:5. doi: 10.1186/s12950-020-0238-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12950-020-0238-7</ArticleId><ArticleId IdType="pmc">PMC7011532</ArticleId><ArticleId IdType="pubmed">32063752</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitiello A., Ferrara F. Low molecular weight heparin, anti-inflammatory/immunoregulatory and antiviral effects, a short update. Cardiovasc. Drugs Ther. 2023;37:277–281. doi: 10.1007/s10557-021-07251-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10557-021-07251-6</ArticleId><ArticleId IdType="pmc">PMC8403694</ArticleId><ArticleId IdType="pubmed">34460031</ArticleId></ArticleIdList></Reference><Reference><Citation>Rider C.C. The potential for heparin and its derivatives in the therapy and prevention of HIV-1 Infection. Glycoconj. J. 1997;14:639–642. doi: 10.1023/A:1018596728605.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1018596728605</ArticleId><ArticleId IdType="pubmed">9298697</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu M., Zhang T., Zhang W., Sun Q., Li H., Li J. Elucidating the interactions between heparin/heparan sulfate and SARS-CoV-2-related proteins—An important strategy for developing novel therapeutics for the COVID-19 pandemic. Front. Mol. Biosci. 2021;7:628551. doi: 10.3389/fmolb.2020.628551.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2020.628551</ArticleId><ArticleId IdType="pmc">PMC7868326</ArticleId><ArticleId IdType="pubmed">33569392</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S.Y., Jin W., Sood A., Montgomery D.W., Grant O.C., Fuster M.M., Fu L., Dordick J.S., Woods R.J., Zhang F. Characterization of heparin and severe acute respiratory syndrome-related Coronavirus 2 (SARS-CoV-2) Spike glycoprotein binding interactions. Antiviral Res. 2020;181:104873. doi: 10.1016/j.antiviral.2020.104873.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2020.104873</ArticleId><ArticleId IdType="pmc">PMC7347485</ArticleId><ArticleId IdType="pubmed">32653452</ArticleId></ArticleIdList></Reference><Reference><Citation>Wasik D., Mulchandani A., Yates M. V A Heparin-Functionalized Carbon Nanotube-Based Affinity Biosensor for Dengue Virus. Biosens. Bioelectron. 2017;91:811–816. doi: 10.1016/j.bios.2017.01.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bios.2017.01.017</ArticleId><ArticleId IdType="pubmed">28152487</ArticleId></ArticleIdList></Reference><Reference><Citation>Hendricks G.L., Velazquez L., Pham S., Qaisar N., Delaney J.C., Viswanathan K., Albers L., Comolli J.C., Shriver Z., Knipe D.M. Heparin octasaccharide decoy liposomes inhibit replication of multiple viruses. Antiviral Res. 2015;116:34–44. doi: 10.1016/j.antiviral.2015.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2015.01.008</ArticleId><ArticleId IdType="pmc">PMC4988063</ArticleId><ArticleId IdType="pubmed">25637710</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Li X., Wu W., Xu X., Xu H., Zhang T. Recent progress of paclitaxel delivery systems: Covalent and noncovalent approaches. Adv. Ther. 2023;6:2200281. doi: 10.1002/adtp.202200281.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adtp.202200281</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye L., Gao Z., Zhou Y., Yin X., Zhang X., Zhang A., Feng Z. A PH-sensitive binary drug delivery system based on poly (Caprolactone)–heparin conjugates. J. Biomed. Mater. Res. Part A. 2014;102:880–889. doi: 10.1002/jbm.a.34735.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jbm.a.34735</ArticleId><ArticleId IdType="pubmed">23554308</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q., Gan L., Tao H., Wang Q., Ye L., Zhang A., Feng Z. The synthesis and application of heparin-based smart drug carrier. Carbohydr. Polym. 2016;140:260–268. doi: 10.1016/j.carbpol.2015.12.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.carbpol.2015.12.007</ArticleId><ArticleId IdType="pubmed">26876853</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y., Chen C.-K., Law W.-C., Mok J., Zou J., Prasad P.N., Cheng C. Well-defined degradable brush polymer–drug conjugates for sustained delivery of Paclitaxel. Mol. Pharm. 2013;10:867–874. doi: 10.1021/mp3004868.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/mp3004868</ArticleId><ArticleId IdType="pubmed">23181264</ArticleId></ArticleIdList></Reference><Reference><Citation>Thacker B., Glass C., Sharfstein S. Advancing to recombinant heparin. Am. Pharm. Rev. 2021;24:10–14.</Citation></Reference><Reference><Citation>Eidi H., Joubert O., Attik G., Duval R.E., Bottin M.C., Hamouia A., Maincent P., Rihn B.H. Cytotoxicity assessment of heparin nanoparticles in NR8383 macrophages. Int. J. Pharm. 2010;396:156–165. doi: 10.1016/j.ijpharm.2010.06.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2010.06.006</ArticleId><ArticleId IdType="pubmed">20542101</ArticleId></ArticleIdList></Reference><Reference><Citation>Paluck S.J., Nguyen T.H., Maynard H.D. Heparin-mimicking polymers: Synthesis and biological applications. Biomacromolecules. 2016;17:3417–3440. doi: 10.1021/acs.biomac.6b01147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.biomac.6b01147</ArticleId><ArticleId IdType="pmc">PMC5111123</ArticleId><ArticleId IdType="pubmed">27739666</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu H., Frederiksen J., Sullenger B.A. Applications and future of aptamers that achieve rapid-onset anticoagulation. RNA. 2023;29:455–462. doi: 10.1261/rna.079503.122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1261/rna.079503.122</ArticleId><ArticleId IdType="pmc">PMC10019365</ArticleId><ArticleId IdType="pubmed">36697262</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>